

**IN THE UNITED STATES DISTRICT COURT FOR  
THE SOUTHERN DISTRICT OF NEW YORK**

BCBSM, INC., d/b/a BLUE CROSS and BLUE  
SHIELD OF MINNESOTA, on behalf of itself  
and those similarly situated,

Plaintiff,

v.

VYERA PHARMACEUTICALS, LLC,  
PHOENIXUS AG, MARTIN SHKRELI, and  
KEVIN MULLEADY,

Defendants.

Case No. 1:21-cv-1884-DLC

**NOTICE OF SETTLEMENT CLASS COUNSEL'S MOTION FOR AN ORDER  
AUTHORIZING DISTRIBUTION OF THE NET SETTLEMENT FUND**

**PLEASE TAKE NOTICE** that upon the accompanying Memorandum of Law, the undersigned counsel for the Settlement Class ("Settlement Class Counsel") will move this Court before the Honorable Denise Cote, United States District Court, Southern District of New York, Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, Room 1910, New York, NY 10007, on a date set by the Court, for an order authorizing distribution of the Net Settlement Fund<sup>1</sup> to qualifying claimants.

In support of this Motion, Settlement Class Counsel rely on the accompanying Memorandum of Law, the Declarations of William V. Reiss and Eric J. Miller, and the exhibits attached thereto. Settlement Class Counsel have submitted a proposed order with this Motion.

---

<sup>1</sup> Where otherwise not defined, the capitalized terms used herein shall have the same meaning as set forth in the defined terms in the January 28, 2022 Settlement Agreement, Dkt. 138-1, the Final Judgment and Order of Dismissal. Dkt. 160, and the previous Declaration of Eric J. Miller and associated exhibits, Dkt. 137.

Respectfully submitted,

Dated: November 7, 2024

By: /s/ William V. Reiss

William V. Reiss

**ROBINS KAPLAN LLP**

1325 Avenue of the Americas, Suite 2601

New York, NY 10019

Telephone: (212) 980-7400

wreissr@robinskaplan.com

*Counsel for Plaintiff BCBSM, Inc., d/b/a  
Blue Cross and Blue Shield of Minnesota, and  
the Settlement Class*

**CERTIFICATE OF SERVICE**

I hereby certify that on the 7th day of November 2024, a copy of the foregoing document was filed electronically on the Court's Electronic Case Filing (ECF) system. A Notice of Electronic Filing (NEF) will be sent by operation of the Court's ECF system to the filing party, the assigned Judge, and any registered user in the case as indicated on the NEF. To the best of my knowledge, there are no other attorneys or parties who require service by U.S. Mail.

November 7, 2024

By: /s/ William V. Reiss  
William V. Reiss  
1325 Avenue of the Americas, Suite 2601  
New York, NY 10019  
Telephone: (212) 980-7400  
Facsimile: (212) 980-7499  
wreiss@robinskaplan.com

*Counsel for Plaintiff BCBSM, Inc., d/b/a  
Blue Cross and Blue Shield of Minnesota, and  
the Settlement Class*

**IN THE UNITED STATES DISTRICT COURT FOR  
THE SOUTHERN DISTRICT OF NEW YORK**

BCBSM, INC., d/b/a BLUE CROSS and  
BLUE SHIELD OF MINNESOTA, on  
behalf of itself and those similarly situated,

Plaintiff,

v.

VYERA PHARMACEUTICALS, LLC,  
PHOENIXUS AG, MARTIN SHKRELI, and  
KEVIN MULLEADY,

Defendants.

Case No. 1:21-cv-1884-DLC

**MEMORANDUM OF LAW IN SUPPORT OF SETTLEMENT CLASS COUNSEL'S  
MOTION FOR AN ORDER AUTHORIZING DISTRIBUTION OF THE NET  
SETTLEMENT FUND**

**TABLE OF CONTENTS**

I. RELEVANT BACKGROUND ..... 1

    A. The Class Settlement..... 1

    B. Class Notice and Claims Administration..... 2

    C. Recent Settlement Payments and Vyera’s Bankruptcy..... 3

    D. The Proposed Distribution of the Net Settlement Fund..... 4

II. The Court Should Authorize Distribution of the Net Settlement Fund ..... 5

III. CONCLUSION..... 7

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Chery v. Conduent Educ. Servs. LLC</i> , No. 1:18-CV-075-DNH-CFH, 2023 WL 2643502 (N.D.N.Y. Mar. 27, 2023) .....	7
<i>In re Agent Orange Prod. Liab. Litig.</i> , 821 F.2d 139 (2d Cir. 1987).....	6
<i>In re Authentidate Holding Corp. Secs. Litig.</i> , No. 05-cv-5323, 2013 WL 324153 (S.D.N.Y. Jan. 25, 2013) .....	6
<i>In re Bank of New York Mellon ADR FX Litig.</i> , No. 16-CV-00212-JPO-JLC, 2021 WL 2709294 (S.D.N.Y. July 1, 2021) .....	6
<i>In re Eletrobras Sec. Litig.</i> , 467 F. Supp. 3d 149 (S.D.N.Y. 2020).....	6
<i>In re Luckin Coffee Inc. Sec. Litig.</i> , No. 20-cv-1293 (JPC), 2023 WL 3483762 (S.D.N.Y. Apr. 21, 2023) .....	7
<i>In re Oxford Health Plans, Inc.</i> , 383 F. App'x 43 (2d Cir. 2010) .....	6
<i>In re Vyera Pharms., LLC</i> , 23-bk-10605-JKS (Bankr. D. Del.).....	4
<i>Martinek v. AmTrust Fin. Servs.</i> , No. 19-CV-8030-KPF, 2023 WL 6121650 (S.D.N.Y. Sept. 19, 2023).....	5
<i>Zients v. LaMorte</i> , 459 F.2d 628 (2d Cir. 1972).....	6

Through this Motion, counsel for the Settlement Class (“Settlement Class Counsel”) respectfully moves the Court for an order authorizing the distribution of the Net Settlement Fund<sup>1</sup> to approved claimants. The Court previously approved the Plan of Allocation on February 10, 2022, Dkt. 141, and granted final approval of the Settlement on June 17, 2022. Dkt. 160. The Settlement anticipated that contingent settlement payments would be paid over time, five of which were made between May 2022 and October 2023. Because a year has passed since Corporate Defendants’ last payment and Settlement Class Counsel does not anticipate additional payments in the near term, now is the appropriate and most cost-efficient time to distribute the Net Settlement Fund. Accordingly, Settlement Class Counsel seeks to distribute the Net Settlement Fund to approved claimants pursuant to the Plan of Allocation. Dkt. 137-3.

## **I. RELEVANT BACKGROUND**

### **A. The Class Settlement**

Plaintiff BCBSM, Inc. filed this class action in March 2021 on behalf of third-party payers who indirectly purchased the pharmaceutical drug Daraprim, alleging Defendants illegally thwarted generic competition for Daraprim in violation of federal and state antitrust, consumer protection, and unjust enrichment laws. Dkt. 1. The parties reached a class settlement in December 2021, which required the Corporate Defendants to make an initial payment of \$7 million into the Class Settlement Fund, plus up to \$21 million in potential contingent payments over time based on specified future revenues. *See* Dkt. 138-1, ¶¶ 60–63. Specifically, the Corporate Defendants are required to make contingent payments to the Class Settlement Fund based on the monetization of

---

<sup>1</sup> Where otherwise not defined, the capitalized terms used herein shall have the same meaning as set forth in the defined terms in the January 28, 2022 Settlement Agreement, Dkt. 138-1, the Final Judgment and Order of Dismissal, Dkt. 160, and the previous Declaration of Eric J. Miller and associated exhibits, Dkt. 137.

any Corporate Asset before December 7, 2026, or the monetization of a Priority Review Voucher before December 7, 2031. *Id.* at ¶ 61.

On February 10, 2022, the Court preliminarily approved the Settlement and approved the Notice Plan and Plan of Allocation. Dkt. 141. The Plan of Allocation directed that the Net Settlement Fund would be distributed to approved claimants on a *pro rata* basis based on the relative size of each approved claim. *Id.* at ¶ 21. The Court also authorized Settlement Class Counsel to pay from the Class Settlement Fund the costs of notice, settlement administration, and taxes without further order of the Court. *Id.* at ¶ 19. On June 17, 2022, the Court awarded attorneys' fees and litigation expenses, Dkt. 159, and granted final approval of the Settlement. Dkt. 160.

**B. Class Notice and Claims Administration**

Pursuant to the Notice Plan, the Claims Administrator disseminated notice of the Settlement and claims process to potential Settlement Class Members and maintained a case-specific website and toll-free helpline for inquiries. Declaration of Eric J. Miller in Support of Settlement Class Counsel's Motion for an Order Authorizing Distribution of the Settlement Fund ("Miller Decl."), ¶ 2. Settlement Class Members who wished to receive a *pro rata* share of the Net Settlement Fund were required to submit a Claim Form to the Claims Administrator by June 1, 2022, together with adequate information to support their claimed purchase amounts. *Id.* at ¶ 4.

To date, the Claims Administrator received 1,371 claims: 1,310 online and 61 via mail. Miller Decl., ¶ 7. The Claims Administrator reviewed all claims to ensure they were complete, to assess eligibility, and to verify the claimed purchase amounts. *Id.* Claims submitted by Settlement Class Members that contained all the requested information and were eligible for distribution were approved. *Id.* ¶¶ 6–8. If a claim was deemed deficient for any reason, claimants were sent letters explaining the reason for the deficiency and were given an opportunity to correct it. *Id.* ¶ 8.



Additionally, all claims in excess of \$100,000 were subject to an audit, as were claims below \$100,000 that warranted additional review. *Id.* at ¶¶ 14–15.

After reviewing each of the submitted claims, the Claims Administrator determined that 142 claims met the relevant criteria for distribution and should be approved (the “Timely Eligible Claims”). *Id.* ¶ 19. The total recognized claim amount for these Timely Eligible Claims is \$268,967,697.40. *Id.* An additional four claims were postmarked or submitted after the June 1, 2022 deadline, but otherwise meet the criteria for a distribution (“Late Eligible Claims”). *Id.* ¶ 20. The total recognized claim amount for these Late Eligible Claims is \$1,169,666.34. *Id.* As set forth below, Settlement Class Counsel requests that the Late Eligible Claims submitted on or before October 17, 2022 be approved. Of the 1,225 claims that the Claims Administrator determined were ineligible for distribution (“Rejected Claims”), 732 were submitted by non-Settlement Class Members, 69 were duplicates, 30 were withdrawn, 38 had uncured deficiencies, and 356 did not pass an audit. *Id.*, ¶ 21. Complete lists of the Timely Eligible Claims, Late Eligible Claims, and Rejected Claims are attached as to the Miller Declaration as Exhibits E–G.

### **C. Recent Settlement Payments and Vyera’s Bankruptcy**

After making their initial \$7 million settlement payment, the Corporate Defendants have made five contingent settlement payments into the Class Settlement Fund between May 9, 2022 and October 27, 2023 totaling \$1,786,436.08. Declaration of William V. Reiss in Support of Class Counsel’s Motion for an Order Authorizing Distribution of the Net Settlement Fund (“Reiss Decl.”), ¶¶ 3–4. As of October 3, 2024, the current balance of the Class Settlement Fund was \$7,137,410.39, which accounts for both interest earned on the settlement payments and withdrawals for settlement-administration expenses, taxes, and Court-authorized attorney’s fees and expenses. Reiss Decl., ¶ 6.

On May 9, 2023, Defendant Vyera Pharmaceuticals, LLC filed for bankruptcy. *See In re Vyera Pharms., LLC*, 23-bk-10605-JKS (Bankr. D. Del.). Settlement Class Counsel thereafter litigated in the bankruptcy court and filed objections to the proposed bankruptcy plan to protect the Settlement Class's rights to receive ongoing settlement payments post-bankruptcy. *Id.*, ECF Nos. 234, 243. On September 13, 2023, Settlement Class Counsel reached a settlement with Vyera to amend the proposed bankruptcy plan to ensure the Settlement Class's rights under the Settlement were unimpaired. *Id.* at ECF No. 270, at 25–26. The bankruptcy court approved the amended bankruptcy plan on October 3, 2023, which appointed Settlement Class Counsel to an Oversight Committee focused on monetizing certain assets that could generate further settlement proceeds for the Settlement Class.<sup>2</sup> *Id.*, ECF No. 313, at 6. The most recent contingent settlement payment was paid into the Class Settlement Fund on October 27, 2023. Reiss Decl., ¶ 6.

#### **D. The Proposed Distribution of the Net Settlement Fund**

Through their ongoing work on the Oversight Committee, Settlement Class Counsel have determined that it is unlikely any additional contingent payments will be paid into the Class Settlement Fund in 2024. The Claims Administrator proposes distributing the Net Settlement Fund to approved claimants via check (or wire transfers, where applicable). Miller Decl., ¶ 25(d). Checks

---

<sup>2</sup> Together with the Liquidating Trustee, the Oversight Committee is working to develop ORL-101, an investigational pharmaceutical drug for a rare disease called Leukocyte Adhesion Deficiency Type II. *See In re Vyera Pharms., LLC*, 23-bk-10605-JKS (Bankr. D. Del.), ECF No. 270, at 39–41. The FDA has granted a Rare Pediatric Disease Designation to ORL-101, meaning that if it is approved by the FDA, it would receive a Priority Review Voucher, which typically can be monetized for around \$100 million. *Id.* Should any such monetization occur, 14% of the proceeds from the Priority Review Voucher shall be paid to the Class Settlement Fund, up to a total of \$19,213,563.92 (equivalent to the \$21 million cap on contingent payments less the \$1,786,436.08 already paid as contingent payments). Dkt. 138-1, ¶¶ 61(b), 62. This 14% amount is equivalent to 70% (the Settlement Class's share in the Global Settlement Fund, compared to Government Plaintiffs' 30% share) of the 20% of Corporate Defendants' asset monetization to be allocated to the Global Settlement Fund.

sent to approved claimants will have an expiration date of 90 days, and any payments not cashed within 120 days will revert to the Class Settlement Fund. *Id.* The Claims Administrator anticipates that its fees and expenses for the work performed in conjunction with the initial distribution of the Net Settlement Fund will be \$16,038.75. Miller Decl., ¶ 24. Settlement Class Counsel and the Claims Administrator also recommend withholding 5% of the Net Settlement Fund in case any payments to claimants need to be adjusted, as well as to pay additional taxes, costs, and administration fees. *Id.* In addition, Settlement Class Counsel request that \$159,384.17 of the Net Settlement Fund be held in reserve to allow payment in the event the Court grants Settlement Class Counsel’s supplemental request for payment of fees totaling \$122,643.61 and reimbursement of expenses totaling \$36,740.56. Any funds remaining in the Class Settlement Fund after the initial distribution is complete will be distributed to approved claimants on a *pro rata* basis if it is feasible and economical to perform a subsequent distribution.<sup>3</sup> *Id.*, ¶ 24.

## **II. The Court Should Authorize Distribution of the Net Settlement Fund**

The Court should authorize Settlement Class Counsel to distribute the Net Settlement Fund to approved claimants pursuant to the Plan of Allocation and as further detailed in the Miller Declaration. Miller Decl., ¶ 26. The Court previously approved the Plan of Allocation, Dkt. 141, at 6–7, and the Claim Administrator’s claim determinations were the result of a detailed review and auditing process to ensure that only valid claims were approved. *Martinek v. AmTrust Fin. Servs.*, No. 19-CV-8030-KPF, 2023 WL 6121650 (S.D.N.Y. Sept. 19, 2023) (approving distribution where claim administrator “completed the process of reviewing all submitted claims”);

---

<sup>3</sup> If Settlement Class Counsel and the Claims Administrator determine that it would not be feasible or economical to distribute the remaining funds, Settlement Class Counsel will seek the Court’s approval to donate the remaining funds to at least one 501(c)(3) non-profit organization, as previously stated. *See* Dkt. 137-3, at 10.

*id.*, ECF No. 115, at 13–15 (detailing review and audit procedures); *see also In re Eletrobras Sec. Litig.*, 467 F. Supp. 3d 149 (S.D.N.Y. 2020) (approving distribution where claim administrator performed rigorous audit); *id.*, No. 15-cv-5754, ECF No. 152, at 5 (describing audit and review procedures). Further, the proposed method of distribution via check and wires will deliver the funds to approved claimants in a prompt and cost-effective manner. *See, e.g., In re Bank of New York Mellon ADR FX Litig.*, No. 16-CV-00212-JPO-JLC, 2021 WL 2709294, at \*1 (S.D.N.Y. July 1, 2021) (order approving distribution plan where Lead Plaintiffs moved to distribute settlement funds promptly via check and wire transfer, if applicable); *see also id.*, ECF No. 173, at 11–12, 21–22 (describing efforts to distribute funds cost-effectively and distribute settlement funds via check and wire transfer).

The Court should also authorize Settlement Class Counsel to distribute the Net Settlement Fund to the four Late But Otherwise Eligible Claims that were submitted after the June 1, 2022 claim deadline but otherwise meet the criteria for distribution. *See Miller Decl.*, ¶ 20. The Court has “inherent power” to accept these eligible yet late-submitted claims. *In re Oxford Health Plans, Inc.*, 383 F. App’x 43, 45 (2d Cir. 2010) (quoting *In re Agent Orange Prod. Liab. Litig.*, 821 F.2d 139, 145 (2d Cir. 1987); *In re Authentidate Holding Corp. Secs. Litig.*, No. 05-cv-5323, 2013 WL 324153, at \*1 (S.D.N.Y. Jan. 25, 2013). “[A] district court entertaining a late-submitted claim to a settlement should examine the equities to determine whether to allow the claim.” *Oxford Health Plans*, 383 F. App’x at 45 (citing *Zients v. LaMorte*, 459 F.2d 628, 630–31 (2d Cir. 1972)); *Authentidate Holding Corp.*, 2013 WL 324153, at \*1.

Approving the Late But Otherwise Eligible Claims would not be unfair or prejudicial. The Late But Otherwise Eligible Claims comprise only 0.4% of the total amount claimed by Settlement Class Members and thus would not meaningfully affect the size any Settlement Class Member’s

distribution. Miller Decl., ¶¶ 19–20. The Late But Otherwise Eligible Claims also have not delayed the distribution of the Net Settlement Fund, as they were submitted between June 1 and October 17, 2022—well before Corporate Defendants’ most recent payment to the Settlement Fund. Miller Decl., ¶ 20. Equities thus favor approving the Late Eligible Claims so that the maximum number of eligible claimants can be compensated. *E.g.*, *Chery v. Conduent Educ. Servs. LLC*, No. 1:18-CV-075-DNH-CFH, 2023 WL 2643502, at \*1 (N.D.N.Y. Mar. 27, 2023) (approving late but otherwise eligible claims); *In re Luckin Coffee Inc. Sec. Litig.*, No. 20-cv-1293 (JPC), 2023 WL 3483762, at \*1 (S.D.N.Y. Apr. 21, 2023) (same).

### III. CONCLUSION

For the foregoing reasons, Settlement Class Counsel respectfully submits that the Court should grant this motion and authorize the distribution of the Net Settlement Fund to approved claimants.

November 7, 2024

By: /s/ William V. Reiss  
William V. Reiss  
**ROBINS KAPLAN LLP**  
1325 Avenue of the Americas, Suite 2601  
New York, NY 10019  
Telephone: (212) 980-7400  
Facsimile: (212) 980-7499  
wreiss@robinskaplan.com  
*Counsel for Plaintiff BCBSM, Inc., d/b/a  
Blue Cross and Blue Shield of Minnesota, and  
the Settlement Class*

**CERTIFICATE OF SERVICE**

I hereby certify that on the 7th day of November 2024, a copy of the foregoing document was filed electronically on the Court's Electronic Case Filing (ECF) system. A Notice of Electronic Filing (NEF) will be sent by operation of the Court's ECF system to the filing party, the assigned Judge, and any registered user in the case as indicated on the NEF. To the best of my knowledge, there are no other attorneys or parties who require service by U.S. Mail.

November 7, 2024

By: /s/ William V. Reiss  
William V. Reiss  
1325 Avenue of the Americas, Suite 2601  
New York, NY 10019  
Telephone: (212) 980-7400  
Facsimile: (212) 980-7499  
wreiss@robinskaplan.com

*Counsel for Plaintiff BCBSM, Inc., d/b/a  
Blue Cross and Blue Shield of Minnesota, and  
the Settlement Class*

**UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK**

BCBSM, INC., d/b/a BLUE CROSS and  
BLUE SHIELD OF MINNESOTA, on behalf  
of itself and those similarly situated,

Plaintiff,

v.

VYERA PHARMACEUTICALS, LLC,  
PHOENIXUS AG, MARTIN SHKRELI, and  
KEVIN MULLEADY,

Defendants.

Civil Action No. 1:21-cv-1884-DLC

**DECLARATION OF ERIC J. MILLER IN SUPPORT OF  
SETTLEMENT CLASS COUNSEL’S MOTION FOR AN ORDER  
AUTHORIZING DISTRIBUTION OF THE SETTLEMENT FUND**

I, Eric J. Miller, declare as follows:

1. I am a Senior Vice President of A.B. Data, Ltd.’s Class Action Administration Company (“A.B. Data”), which has its corporate office in Milwaukee, Wisconsin. I am over 21 years of age and am not a party to the above-captioned action (the “Action”).<sup>1</sup> I have personal knowledge of the facts set forth herein and, if called as a witness, could and would testify competently thereto.

2. Pursuant to the Court’s February 10, 2022 Order Granting Plaintiff’s Unopposed Motion for Preliminary Approval of Class Action Settlement; Certification of Settlement Class; Approval of Notice Plan; Approval of Plan of Allocation; and Entry of Settlement Approval

---

<sup>1</sup>Unless otherwise defined herein, all capitalized terms have the meanings set forth in the Settlement Agreement dated January 28, 2022 (Dkt. 138-1) and the previous Declaration of Eric J. Miller and associated exhibits (Dkt. 137).

Schedule and Related Procedures (Dkt. 141), A.B. Data was appointed by the Court to act as the Notice Provider and Claims Administrator in connection with the Settlement of the Action. As the Notice Provider and Claims Administrator, A.B. Data has, among other things: (i) disseminated notice to potential Settlement Class Members; (ii) created and continues to maintain a toll-free helpline for inquiries during the course of the administration; (iii) created and continues to maintain a website for the Settlement (the “Settlement Website”) and posted case-specific documents on it; and (vi) received and processed each Claim Form received by the Notice and Claims Administrator from Settlement Class Members.

3. On June 17, 2022, the Court granted final approval of the Settlement in its Final Judgment and Order of Dismissal (Dkt. 160). A.B. Data has completed processing all Claims received through October 17, 2022, in accordance with the terms of the Settlement Agreement and the Plan of Allocation set forth in the Notice, and hereby submits its administrative determinations accepting and rejecting the Claim Forms in preparation for a distribution of the Net Settlement Fund to Authorized Claimants. A.B. Data also presents this declaration in support of Settlement Class Counsel’s Motion for an Order Authorizing Distribution of the Settlement Fund.

**PROCEDURES FOLLOWED IN PROCESSING CLAIMS**

4. Under the terms of the Preliminary Approval Order and as set forth in the Notice, each Settlement Class Member who wished to be eligible to receive a distribution from the Net Settlement Fund was required to complete and submit to A.B. Data a properly executed Claim Form postmarked (if mailed) or online no later than June 1, 2022, together with adequate supporting claims data and information in support of the purchase amounts reported in the Claim Form.



5. In preparation for receiving and processing Claims, A.B. Data: (i) conferred with Settlement Class Counsel to define the guidelines for processing Claims; (ii) created a unique database to store Claim details, images of Claims, and supporting documentation (the “Settlement Database”); (iii) trained staff in the specifics of the Settlement so that Claims would be properly processed; (iv) formulated a system so that telephone and email inquiries would be properly responded to; (v) developed various computer programs and screens for entry of Settlement Class Members’ identifying information and their purchase information; and (vi) developed a “calculation module” that would calculate Recognized Claims pursuant to the Court-approved Plan of Allocation for the Net Settlement Fund stated in the Notice.

#### **PROCESSING CLAIMS**

6. Through October 17, 2022, A.B. Data has received and fully processed 1,371 Claims.

7. Of the 1,371 Claims, 61 are Claims submitted on paper or via email and 1,310 are Claims submitted via the online filing component of the Settlement Website. Once received, paper Claims were opened and prepared for scanning. This process included unfolding documents, removing staples, copying nonconforming-sized documents, and sorting documents. This manual task of preparing the paper Claims is very laborious and time intensive. Once prepared, paper Claims were scanned into the Settlement Database together with all submitted documentation. Subsequently, each Claim was assigned a unique Claim number. Once scanned, the information from each Claim Form, including the Claimant’s contact information, and the Claimant’s purchase information listed on the Claim Form, was entered into the Settlement Database. Once entered into the Settlement Database, each Claim was reviewed to verify that all required information had been provided. Any purchase data provided by the Claimant in support of the Claim was reviewed to

verify the purchases or reimbursements were for Daraprim during the period from August 7, 2015, through January 28, 2022.

8. A.B. Data's data-entry staff utilized internal codes ("flags") to identify and classify deficiency or ineligibility conditions existing within those Claims. A.B. Data's staff assigned appropriate flags to the Claims as they were processed. For example, where a Claimant submitted a Claim but did not properly sign the Claim Form, that Claim would receive a flag that denoted the deficiency. A.B. Data's staff used similar defect flags to denote other ineligible conditions, such as duplicate Claims. These flags would indicate to A.B. Data that the Claimant was not eligible to receive any payment from the Net Settlement Fund with respect to that Claim unless the deficiency was cured in its entirety.

#### **THE DEFICIENCY PROCESS**

9. The "Deficiency Process," which primarily involved mailing letters to Claimants and responding to communications from Claimants by email and/or telephone, was intended to assist Claimants in properly completing their otherwise deficient submissions so that they could be eligible to participate in the Settlement.

10. Of the 1,371 Claims received, A.B. Data initially determined that deficient Claims were those for which the Claimant:

(a) omitted the Federal Employer Identification Number ("FEIN") for the Claimant;

(b) did not sign the Claim Form;

(c) did not list the total amount paid or reimbursed for Daraprim during the period from August 7, 2015, through January 28, 2022;

(d) did not purchase Daraprim during the period from August 7, 2015, through January 28, 2022; or

(e) did not include the necessary supporting documentation as required in Part II of the Claim Form.

11. A.B. Data sent letters and emails, where an email address was provided with the Claim, describing the defect(s) in the Claims and what steps, if any, were necessary to cure the defect(s) in these Claims. These letters (the “Deficiency Letters”) advised Claimants that they had to submit appropriate information and/or documentary evidence to complete the Claim within twenty (20) days from the date of the letter, or the Claim would be recommended for rejection to the extent that the deficiency condition was not cured. The Deficiency Letter also advised Claimants of their right to contest these administrative determinations, and of the need to submit written statements to A.B. Data requesting Court review of their Claims and setting forth the basis for such requests. Examples of the Deficiency Letters are attached as **Exhibit A**.

12. In addition, A.B. Data sent letters and emails, where an email address was provided with the Claim, to Claimants whose Claims were determined to be ineligible because the Claim was duplicative of a previously filed Claim (for example, where a Claim was submitted online to A.B. Data and the original hard-copy was sent by mail and received at a later date), the Claim was submitted by a consumer, or the Claim was withdrawn by the filer. Examples of these letters (the “Ineligibility Letters”) are attached as **Exhibit B**.

13. Claimants’ responses to Deficiency Letters and Ineligibility Letters were scanned into the Settlement Database and associated with the corresponding Claims. A.B. Data’s team of processors then carefully reviewed and evaluated the responses. If a Claimant’s response corrected the defect(s) in a Claim, A.B. Data manually updated the Settlement Database to reflect the changes in the status of the Claim.

### AUDITS

14. A.B. Data audited all Claims listing purchases over \$100,000 by reviewing the purchase information included with each Claim to verify the amount claimed and that the purchases or reimbursements for Daraprim were made during the period from August 7, 2015, through January 28, 2022. A.B. Data also reviewed documentation for Claims under \$100,000 that provided purchase information although Claimants were not required to furnish such documentation. As a result of the audit and based on the documentation submitted, A.B. Data adjusted some Claim amounts upward or downward. A.B. Data notified the Claimants in writing, of any adjustment to their Claim and provided them with an opportunity to dispute the findings by responding with any additional documentation to support their position.

15. All Claims were subject to review and/or audit by the Claims Administrator. A.B. Data selected Claims for additional audit, in consultation with Settlement Class Counsel, where a) the Claimant submitted a Claim just below the required documentation threshold of \$100,000; b) the claimed amount appeared high compared to similar-sized entities; c) third-party filing entities filed multiple Claims lacking sufficient supporting documents; and/or d) members of A.B. Data's staff identified a Claim that was potentially inaccurate or fraudulent.

16. A.B. Data sent letters by mail, and email if available, to each of these Claimants requesting that they provide additional documentation to further support the purchase or reimbursement amount. The letter advised the Claimant that failure to provide the required information would result in the disallowance of their Claim. A sample of this letter is attached hereto as **Exhibit C**. A.B. Data reviewed and processed the responses to these letters. A.B. Data updated the Claim records to the extent sufficient documentation was provided.

### **COURT REVIEW**

17. As noted above, Claimants were advised that they had the right to contest A.B. Data's administrative determination of deficiencies or ineligibility within twenty (20) days from the date of notification and that they could request that the dispute be submitted to the Court for review. A.B. Data received two requests from Claimants for Court Review of the determination of their Claims in response to audit letters. In each instance, A.B. Data sent the audit letters because the entities did not appear to be Third-Party Payors. A.B. Data sent follow-up letters by mail and email to the two Claimants requesting a Court Review of their Ineligible Claim and requested they provide additional documentation to further support the purchase or reimbursement amount, and necessary documentation to support they are not a consumer filer. The letter advised the Claimants that failure to provide the required information would result in the disallowance of their Claim. A sample of this letter is attached hereto as **Exhibit D**. A.B. Data did not receive any response to these letters.

18. In aggregate, A.B. Data sent over 1,185 letters to Claimants by First-Class U.S. Mail and, in many cases, also sent emails and placed telephone calls to the Claimants in an effort to resolve the problem that rendered the Claim deficient or ineligible.

### **RECOMMENDATIONS FOR APPROVAL AND REJECTION**

#### **Timely Submitted and Valid Claims**

19. A total of 1,297 Claims were received or postmarked on or before June 1, 2022, the Court-approved Claim submission deadline, of which 142 Claims were determined by A.B. Data to be eligible to participate in the Settlement and are recommended for approval ("Timely Eligible Claims"). The total Recognized Claim amount for these Timely Eligible Claims is \$268,967,697.40.

### **Late But Otherwise Eligible Claims**

20. A total of 74 Claims were received or postmarked after June 1, 2022, the Court-approved Claim submission deadline, but received on or before October 17, 2022. Of those 74 late Claims, A.B. Data determined four to be otherwise eligible and are recommended for approval (“Late But Otherwise Eligible Claims”). The total Recognized Claim amount for these Late But Otherwise Eligible Claims is \$1,169,666.34.

### **Rejected Claims**

21. After A.B. Data processed the responses to Deficiency and Ineligibility Letters, there remains a total of 1,225 Claims that A.B. Data recommends should be rejected by the Court (“Rejected Claims”) for the following reasons:

- 69 Duplicate Claims;
- 30 Claim Withdrawn;
- 38 Deficient Claims, Never Cured
- 732 Claims not a TPP; and
- 356 Claims with Insufficient Response to Audit.

### **Lists of All Claims**

22. Attached hereto as Exhibits E through G are listings of all the Claims:

**Exhibit E** lists the Timely Eligible Claims and shows each Claimant’s Recognized Claim;

**Exhibit F** lists the Late But Otherwise Eligible Claims and shows each Claimant’s Recognized Claim; and

**Exhibit G** lists the Rejected Claims and the reasons for rejection.

23. The names of these entities in Exhibits E through G have been redacted to protect their privacy. Unredacted copies have been provided to Settlement Class Counsel and are available to be filed with the Court upon request.

### **FEES AND DISBURSEMENTS**

24. A.B. Data agreed to be the Notice Provider and Claims Administrator in exchange for payment of its fees and out-of-pocket expenses. Settlement Class Counsel received reports on and invoices for the work A.B. Data performed with respect to the provision of notice and administration of the Settlement. A.B. Data anticipates that its fees and expenses for the work performed in conjunction with the initial distribution of the Net Settlement Fund will be \$16,038.75. Attached hereto as **Exhibit H** is an estimate for the work that will be performed and the costs that will be incurred in connection with the initial distribution of the Net Settlement Fund. Should the estimate of fees and expenses to conduct the initial distribution of the Net Settlement Fund exceed the actual cost, the excess will be returned to the Net Settlement Fund and will be available for subsequent distribution to Authorized Claimants.

### **DISTRIBUTION PLAN FOR THE NET SETTLEMENT FUND**

25. Should the Court concur with A.B. Data's determinations concerning provisionally accepted and rejected claims, including the late claims, A.B. Data recommends the following distribution plan:

(a) A.B. Data will establish a reserve of 5% of the Net Settlement Fund to allow for any necessary adjustments in payments upon sufficient proof and/or to pay additional taxes, costs, and administration fees. Any funds remaining from the reserve after the initial distribution will be included as part of the second distribution to the members of the Settlement Class who or which received an initial distribution;

(b) A.B. Data will establish a reserve of \$159,384.17 to allow for payment of Settlement Class Counsel's supplemental request for attorney's fees and expenses (\$122,643.61 for requested fees and \$36,740.56 for requested expenses), should that request be granted;

(c) The remaining Net Settlement Fund will be allocated on a *pro rata* basis to Eligible Claimants in accordance with the Plan of Allocation approved by the Court;

(d) A.B. Data will promptly mail, or process wire payments if requested, each Eligible Claimant its appropriate share of the Net Settlement Fund. The checks will have a stale date of 90 days to encourage Eligible Claimants to promptly cash their distribution checks and to avoid or reduce future expenses related to unpaid distributions. For any checks returned as undeliverable or not cashed, A.B. Data will make reasonable and diligent efforts to have Eligible Claimants cash their checks. At such time that Settlement Class Counsel and A.B. Data have determined that reasonable and diligent efforts have been exhausted, but no earlier than one hundred twenty days from the issue of the checks, the payments to Eligible Claimants that have not been cashed will revert back to the Settlement Fund;

(e) If there is a balance remaining in the Settlement Fund after A.B. Data has made reasonable and diligent efforts to have Eligible Claimants cash their distribution checks, and at least 120 days from the date of the initial distribution, and after any necessary adjustments in payments upon sufficient proof and/or to pay additional taxes, costs, and administration fees, A.B. Data will consult with Settlement Class Counsel and conduct a second distribution if feasible and economical. A.B. Data will redistribute the remaining funds, along with any remaining balance of the reserve, on a *pro rata* basis after reserving any additional taxes, costs, and administration fees to the Eligible Claimants who cashed their initial distribution checks and who would receive at least \$10.00 from such redistribution; and



(f) at such time as Settlement Class Counsel, in consultation with A.B. Data, determines that further distribution of the funds remaining in the Settlement Fund is not cost-effective, the remaining funds will be available for donation to one or more 501(c)(3) non-profit organization(s) proposed by Class Counsel and approved by the Court.

**CONCLUSION**

26. A.B. Data respectfully requests that the Court enter an Order approving its administrative determinations accepting and rejecting the claims submitted herein and approving the proposed distribution plan.

I declare under the penalty of perjury under the laws of the United States of America that the foregoing is true and correct to the best of my knowledge. Executed this 1st day of November, 2024 in Palm Beach Gardens, Florida.



Eric J. Miller

# EXHIBIT A

DARAPRIM TPP SETTLEMENT

C/O A.B. DATA, LTD.

PO BOX 173115

MILWAUKEE, WI 53217

ATTN

**NOTICE OF DEFICIENCY AND  
REQUEST FOR ADDITIONAL INFORMATION**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Vyera Pharmaceuticals, et al.* However, we noted one or more deficiencies in the Claim you submitted. In order to resolve the deficient condition(s) within your Claim, you must submit a written response with any required information as specified below, postmarked no later than the Response Deadline printed above. Please include a copy of this notice with your response. **Failure to respond to this request with the required information to cure the deficient condition(s) identified below by the Response Deadline will result in the disallowance of your Claim.**

**Insufficient Documentation**

You claimed \$100,000 or more paid or reimbursed for Daraprim and failed to provide OR provided insufficient documentation with your Claim.

Because you are claiming \$100,000 or more paid or incurred for Daraprim, you must provide documentation with your Claim or the missing documentation to justify your claimed amount. The Addendum included with this letter provides further details in the Claim Documentation Requirements section.

If you disagree with the deficient condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the full or partial rejection of the Claim; (3) state your argument(s) for why you are contesting the full or partial rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response

to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the Claim Number listed above in any communication.

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

**ADDENDUM – DARAPRIM TPP SETTLEMENT**Claim Number: [REDACTED]**MISSING TAX ID**

In the box below, please type or print the Tax Identification Number for the Settlement Class Member.

Tax Identification Number	
---------------------------	--

**MISSING AMOUNT**

In the box below, please type or print the total amounts paid or reimbursed for Daraprim in any of the eligible states and territories listed below during the period from August 7, 2015, through January 28, 2022. The eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

VALEANT-BRANDED DRUG PURCHASED FROM OR FULFILLED BY PHILIDOR NETWORK PHARMACY	TOTAL AMOUNT PAID
Amounts Paid or Incurred from January 2, 2013, through November 9, 2015.	\$

You **must** submit claims data and information in support of the purchase amounts stated above if your Total Amount Paid is more than \$100,000 (see Part III). If your Total Amount Paid is \$100,000 or less, you need not provide complete claims data with the Claim, but the Claims Administrator may later require supporting documentation.

**MISSING SIGNATURE**

By signing below, you confirm under the penalties of perjury that all the information provided in your previously submitted Claim, along with any additional information provided, is true, correct, and complete. *Please note that signing a Claim that contains false information could constitute perjury.*

Signature

Position/Title

Print Name

Date

**CLAIM DOCUMENTATION REQUIREMENTS**

You must provide all the information requested in “Part II: Amount Claimed” of the Claim Form, available on the Settlement website, [www.DaraprimTPPSettlement.com](http://www.DaraprimTPPSettlement.com). You must submit claims data and information in support of the purchase amounts if your total net claim amount is more than \$100,000. Your claimed purchase amounts must be for Daraprim Purchases or Reimbursements between August 7, 2015, and January 28, 2022, in any of these eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

If you must submit claims data and information, it is mandatory that you provide the data for all categories listed below. Affidavits that do not include the information listed below will not be accepted:

- a) Unique patient identification number or code
- b) NDC Number (a list of NDC Numbers is available on the Settlement website) – e.g., 00000-0000-00
- c) Fill Date or Date of Service – e.g., 01/01/2007
- d) State or Territory of Service – e.g. California
- e) Amount Billed (not including dispensing fee) – e.g., \$40.00
- f) Amount Paid by TPP net of co-pays, deductibles, and co-insurance – e.g., \$20.00

If you are submitting a Claim Form on behalf of multiple Settlement Class Members, also provide the following information for each prescription:

- g) Plan or Group Name
- h) Plan or Group FEIN – provide group number for each transaction

An exemplar spreadsheet containing these categories is available on the Settlement website. In addition, an Excel spreadsheet can be downloaded from the Settlement website. Please use this format if possible. A list of the NDCs that will be considered by the Claims Administrator is also provided at the Settlement website.

DARAPRIM TPP SETTLEMENT

C/O A.B. DATA, LTD.

PO BOX 173115

MILWAUKEE, WI 53217



**NOTICE OF DEFICIENCY AND  
REQUEST FOR ADDITIONAL INFORMATION**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Viera Pharmaceuticals, et al.* However, we noted one or more deficiencies in the Claim you submitted. In order to resolve the deficient condition(s) within your Claim, you must submit a written response with any required information as specified below, postmarked no later than the Response Deadline printed above. Please include a copy of this notice with your response. **Failure to respond to this request with the required information to cure the deficient condition(s) identified below by the Response Deadline will result in the disallowance of your Claim.**

**Missing Amount**

You neglected to provide the total amount paid or reimbursed for Daraprim.

To resolve this deficiency, please provide the total amount paid or reimbursed for Daraprim dispensed in the eligible states and territories net of co-pays, deductibles, and co-insurance in the Missing Amount section of the attached Addendum. You must also sign and date the attached Addendum.

If you disagree with the deficient condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the full or partial rejection of the Claim; (3) state your argument(s) for why you are contesting the full or partial rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

**ADDENDUM – DARAPRIM TPP SETTLEMENT**

Claim Number: [REDACTED]

**MISSING TAX ID**

In the box below, please type or print the Tax Identification Number for the Settlement Class Member.

Tax Identification Number	
---------------------------	--

**MISSING AMOUNT**

In the box below, please type or print the total amounts paid or reimbursed for Daraprim in any of the eligible states and territories listed below during the period from August 7, 2015, through January 28, 2022. The eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

VALEANT-BRANDED DRUG PURCHASED FROM OR FULFILLED BY PHILIDOR NETWORK PHARMACY	TOTAL AMOUNT PAID
Amounts Paid or Incurred from January 2, 2013, through November 9, 2015.	\$

You **must** submit claims data and information in support of the purchase amounts stated above if your Total Amount Paid is more than \$100,000 (see Part III). If your Total Amount Paid is \$100,000 or less, you need not provide complete claims data with the Claim, but the Claims Administrator may later require supporting documentation.

**MISSING SIGNATURE**

By signing below, you confirm under the penalties of perjury that all the information provided in your previously submitted Claim, along with any additional information provided, is true, correct, and complete. *Please note that signing a Claim that contains false information could constitute perjury.*

Signature \_\_\_\_\_ Position/Title \_\_\_\_\_

Print Name \_\_\_\_\_ Date \_\_\_\_\_

**CLAIM DOCUMENTATION REQUIREMENTS**

You must provide all the information requested in “Part II: Amount Claimed” of the Claim Form, available on the Settlement website, [www.DaraprimTPPSettlement.com](http://www.DaraprimTPPSettlement.com). You must submit claims data and information in support of the purchase amounts if your total net claim amount is more than \$100,000. Your claimed purchase amounts must be for Daraprim Purchases or Reimbursements between August 7, 2015, and January 28, 2022, in any of these eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

If you must submit claims data and information, it is mandatory that you provide the data for all categories listed below. Affidavits that do not include the information listed below will not be accepted:

- a) Unique patient identification number or code
- b) NDC Number (a list of NDC Numbers is available on the Settlement website) – e.g., 00000-0000-00
- c) Fill Date or Date of Service – e.g., 01/01/2007
- d) State or Territory of Service – e.g. California
- e) Amount Billed (not including dispensing fee) – e.g., \$40.00
- f) Amount Paid by TPP net of co-pays, deductibles, and co-insurance – e.g., \$20.00

If you are submitting a Claim Form on behalf of multiple Settlement Class Members, also provide the following information for each prescription:

- g) Plan or Group Name
- h) Plan or Group FEIN – provide group number for each transaction

An exemplar spreadsheet containing these categories is available on the Settlement website. In addition, an Excel spreadsheet can be downloaded from the Settlement website. Please use this format if possible. A list of the NDCs that will be considered by the Claims Administrator is also provided at the Settlement website.



# EXHIBIT B

DARAPRIM TPP SETTLEMENT  
C/O A.B. DATA, LTD.  
PO BOX 173115  
MILWAUKEE, WI 53217

ATTN

**NOTICE OF INELIGIBILITY**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Vyera Pharmaceuticals, et al.* Based on our review, your Claim is ineligible for recovery for the reason listed below.

**Duplicate Claim**

The Claim Number listed above is ineligible because the claim is duplicative of another Claim (Claim #: [REDACTED]). Claim No. [REDACTED] is being processed separately, and you will be notified separately if that claim is deficient or ineligible for recovery.

If you accept this determination, you do not need to do anything in response to this letter.

If you disagree with the determination, you must advise us in writing by the Response Deadline listed above. Your letter must also include documentation supporting your position.

If you disagree with the ineligibility condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the rejection of the Claim; (3) state your argument(s) for why you are contesting the rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response

to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the Claim Number listed above in any communication.

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

DARAPRIM TPP SETTLEMENT  
C/O A.B. DATA, LTD.  
PO BOX 173115  
MILWAUKEE, WI 53217

ATTN

**NOTICE OF INELIGIBILITY**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Vyera Pharmaceuticals, et al.* Based on our review, your Claim is ineligible for recovery for the reason listed below.

**Consumer Claim**

The Claim Number listed above is ineligible because the claim is submitted on behalf of a consumer. Only Third-Party Payors are eligible to submit Claims in this matter, not individual consumers.

If you accept this determination, you do not need to do anything in response to this letter.

If you disagree with the determination, you must advise us in writing by the Response Deadline listed above. Your letter must also include documentation supporting your position.

If you disagree with the ineligibility condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the rejection of the Claim; (3) state your argument(s) for why you are contesting the rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the

Claim Number listed above in any communication.

Sincerely yours,

A.B. DATA, LTD.

Claims Administrator

DARAPRIM TPP SETTLEMENT  
C/O A.B. DATA, LTD.  
PO BOX 173115  
MILWAUKEE, WI 53217

ATTN

**NOTICE OF INELIGIBILITY**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Vyera Pharmaceuticals, et al.* Based on our review, your Claim is ineligible for recovery for the reason listed below.

**Withdrawn Claim**

We have received your request to withdraw the above-noted Claim Form that you submitted in connection with the Daraprim TPP Settlement. In accordance with the request, we have withdrawn the claim and, as such, even if it would have been otherwise eligible to receive a payment from the proceeds of the settlement, no payment will be made on it.

If the withdrawal request was submitted in error and you wish to reinstate the Claim, you must advise us in writing by the Response Deadline listed above.

If you disagree with the ineligibility condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the rejection of the Claim; (3) state your argument(s) for why you are contesting the rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response

to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the Claim Number listed above in any communication.

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

DARAPRIM TPP SETTLEMENT

C/O A.B. DATA, LTD.

PO BOX 173115

MILWAUKEE, WI 53217

ATTN [Redacted]

**NOTICE OF DEFICIENCY AND  
REQUEST FOR ADDITIONAL INFORMATION**

**DATE:** [Redacted]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [Redacted]  
**RESPONSE DEADLINE:** [Redacted]

Dear Claimant:

We have processed the Third-Party Payor Claim Form ("Claim") and any supporting documentation that you submitted in *BCBSM, Inc. v. Viera Pharmaceuticals, et al.* However, we noted one or more deficiencies in the Claim you submitted. In order to resolve the deficient condition(s) within your Claim, you must submit a written response with any required information as specified below, postmarked no later than the Response Deadline printed above. Please include a copy of this notice with your response. **Failure to respond to this request with the required information to cure the deficient condition(s) identified below by the Response Deadline will result in the disallowance of your Claim.**

**Audit**

You claimed that your total amount paid or reimbursed for Daraprim from August 7, 2015 through January 29, 2022 is \$ [Redacted]

Pursuant to Part II of the Claim Form, we request that you provide documentation that supports your Claim for total amounts paid or incurred for Daraprim that was purchased in the eligible states or territories as identified in the Claim Documentation Requirements section of the attached Addendum.

If you disagree with the deficient condition(s) identified in this notice, you may contact us for assistance and/or request Court review of our administrative determination regarding your Claim.

To request Court review of your Claim, you must send a letter to the Claims Administrator at the address printed at the top of this notice, postmarked no later than the Response Deadline set forth above. Your letter must: (1) include a copy of this notice; (2) specifically state that you request Court review of the full or partial rejection of the Claim; (3) state your argument(s) for why you are contesting the full or partial rejection of the Claim; and (4) include any and all documentation supporting your argument(s). If the dispute concerning your Claim cannot be resolved, your Claim will be presented to the Court for review, which may include public filing of your Claim and supporting documentation with the Court with financial account numbers and certain other information redacted. **PLEASE NOTE: COURT REVIEW SHOULD ONLY BE SOUGHT IF YOU DISAGREE WITH THE CLAIMS ADMINISTRATOR'S DETERMINATION REGARDING YOUR CLAIM.**

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response



to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the Claim Number listed above in any communication.

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

**ADDENDUM – DARAPRIM TPP SETTLEMENT**Claim Number: [REDACTED]**MISSING TAX ID**

In the box below, please type or print the Tax Identification Number for the Settlement Class Member.

Tax Identification Number	
---------------------------	--

**MISSING AMOUNT**

In the box below, please type or print the total amounts paid or reimbursed for Daraprim in any of the eligible states and territories listed below during the period from August 7, 2015, through January 28, 2022. The eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

VALEANT-BRANDED DRUG PURCHASED FROM OR FULFILLED BY PHILIDOR NETWORK PHARMACY	TOTAL AMOUNT PAID
Amounts Paid or Incurred from January 2, 2013, through November 9, 2015.	\$

You **must** submit claims data and information in support of the purchase amounts stated above if your Total Amount Paid is more than \$100,000 (see Part III). If your Total Amount Paid is \$100,000 or less, you need not provide complete claims data with the Claim, but the Claims Administrator may later require supporting documentation.

**MISSING SIGNATURE**

By signing below, you confirm under the penalties of perjury that all the information provided in your previously submitted Claim, along with any additional information provided, is true, correct, and complete. *Please note that signing a Claim that contains false information could constitute perjury.*

Signature

Position/Title

Print Name

Date

**CLAIM DOCUMENTATION REQUIREMENTS**

You must provide all the information requested in “Part II: Amount Claimed” of the Claim Form, available on the Settlement website, [www.DaraprimTPPSettlement.com](http://www.DaraprimTPPSettlement.com). You must submit claims data and information in support of the purchase amounts if your total net claim amount is more than \$100,000. Your claimed purchase amounts must be for Daraprim Purchases or Reimbursements between August 7, 2015, and January 28, 2022, in any of these eligible states and territories are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, West Virginia, and Wisconsin.

If you must submit claims data and information, it is mandatory that you provide the data for all categories listed below. Affidavits that do not include the information listed below will not be accepted:

- a) Unique patient identification number or code
- b) NDC Number (a list of NDC Numbers is available on the Settlement website) – e.g., 00000-0000-00
- c) Fill Date or Date of Service – e.g., 01/01/2007
- d) State or Territory of Service – e.g. California
- e) Amount Billed (not including dispensing fee) – e.g., \$40.00
- f) Amount Paid by TPP net of co-pays, deductibles, and co-insurance – e.g., \$20.00

If you are submitting a Claim Form on behalf of multiple Settlement Class Members, also provide the following information for each prescription:

- g) Plan or Group Name
- h) Plan or Group FEIN – provide group number for each transaction

An exemplar spreadsheet containing these categories is available on the Settlement website. In addition, an Excel spreadsheet can be downloaded from the Settlement website. Please use this format if possible. A list of the NDCs that will be considered by the Claims Administrator is also provided at the Settlement website.

# EXHIBIT D

DARAPRIM TPP SETTLEMENT  
C/O A.B. DATA, LTD.  
PO BOX 173115  
MILWAUKEE, WI 53217

ATTN

**REQUEST FOR ADDITIONAL INFORMATION**

**DATE:** [REDACTED]  
**RE:** Daraprim TPP Settlement  
**CLAIM NUMBER:** [REDACTED]  
**RESPONSE DEADLINE:** [REDACTED]

Dear Claimant:

We are in receipt of your request for a Court review of your claim. The Settlement Class in this matter includes:

All entities that, for consumption by their members, employees, insureds, participants, or beneficiaries, and not for resale, indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of Daraprim during the Settlement Class Period (August 7, 2015, through January 28, 2022). Excluded from the Settlement Class are the following:

- a) Natural person consumers;
- b) Defendants and their employees, affiliates, parents, and subsidiaries, whether or not named in the Complaint;
- c) All federal and state governmental entities except for cities, towns, municipalities, or counties with self-funded
- d) prescription drug plans;
- e) Fully insured health plans (*i.e.*, health plans that purchased insurance covering 100% of their reimbursement
- f) obligation to members); and
- g) Judges assigned to this case and any members of their immediate families.

The types of third-party payor entities that might fall within the Settlement Class include health insurance companies; union health and welfare benefit plans; self-insured employers; and entities with self-funded plans that contract with a health insurance company or other entity to serve as a third-party claims administrator to administer their prescription drug benefits.

To verify that you are a member of the Settlement Class, please provide the following:

- 1. a copy of this notice;
- 2. a copy of your business license as registered with the State;
- 3. a copy of your contract with your health plan insurer, or a copy of your contract with the pharmacy benefits manager of your health plan;
- 4. state your argument(s) for why you are contesting the rejection of the Claim; and
- 5. include any and all transaction data supporting your claimed amount of \$50,000.00. The transaction data should include the following:

- a) Unique patient identification number or code
- b) NDC Number – *e.g.*, 00000-0000-00
- c) Fill Date or Date of Service – *e.g.*, 08/07/2015
- d) Location (State) of Service – *e.g.*, CA
- e) Amount Billed (not including dispensing fee) – *e.g.*, \$40.00
- f) Amount Paid by TPP net of co-pays, deductibles, and co-insurance – *e.g.*, \$20.00

If you have any questions about this notice or if you want to confirm the status of your Claim after you submit a response to this notice, please contact us at 877-316-0144 or email us at [info@DaraprimTPPSettlement.com](mailto:info@DaraprimTPPSettlement.com). Please reference the Claim Number listed above in any communication. **Failure to respond to this request with the required information by the Response Deadline will result in the disallowance of your Claim.**

Sincerely yours,

A.B. DATA, LTD.  
Claims Administrator

# EXHIBIT E

**Exhibit Summary: Total Claims: 142 Claims;**

Claim Number	Authorized Claim
149438190	\$ 201.24
149438188	\$ 71.05
149438187	\$ 3,723.61
149438185	\$ 64,914.00
149438184	\$ 250,942.35
149438180	\$ 65,645.20
149438175	\$ 60,861,054.96
149438174	\$ 266,556.00
149438173	\$ 93,836.00
149438169	\$ 16,859.95
149438168	\$ 147,443.00
149438166	\$ 2,480,089.55
149438165	\$ 19,820,821.72
149438164	\$ 529,392.06
149438161	\$ 7,054,686.77
149438160	\$ 1,383,707.29
149438159	\$ 2,266.64
149438158	\$ 2,367.10
149438157	\$ 9,978,530.37
149438156	\$ 34,755,035.18
149438151	\$ 11,627.94
149078802	\$ 432,179.50
186391634	\$ 353,848.88
149078799	\$ 266,246.96
149078801	\$ 30,600.00
149078800	\$ 1,373.52
149438124	\$ 620,372.56
149438116	\$ 7,394,081.77
149438115	\$ 281,887.31
149438112	\$ 1,862.39
149438109	\$ 617,255.90
149438102	\$ 55,974.57
149438100	\$ 1,973,929.86
149438087	\$ 286,442.10
149438086	\$ 1,237,060.08
149438085	\$ 136,782.20
149438084	\$ 65,031.70
149438070	\$ 1,325,656.00
149438069	\$ 1,255,390.12
149438041	\$ 5,500.00
149437995	\$ 65,375.67
149437993	\$ 33,318.95
149437989	\$ 500.00
149437987	\$ 288,594.00

149437986	\$	3,774,391.06
149437983	\$	47,775.75
149437982	\$	30,801.00
149437981	\$	32,545.65
149437968	\$	19,545.85
149437967	\$	571,002.71
149437964	\$	136,645.79
149437963	\$	1,032,100.00
149437951	\$	379,013.20
149437949	\$	29,378,472.03
149437940	\$	119,882.80
149437938	\$	9,096.63
149437937	\$	172,665.70
149437936	\$	917,878.50
149437933	\$	181,033.40
149437931	\$	868,759.18
149437916	\$	222,002.10
149437912	\$	126,519.75
149437909	\$	50,659.90
149437883	\$	952,375.47
149437880	\$	88,184.17
149437855	\$	555,576.28
149437850	\$	674,122.84
149437849	\$	21,765.00
149437844	\$	33,760.17
149437842	\$	44,280.64
149437841	\$	626,566.41
149437839	\$	45,531.50
149437837	\$	47,994.00
149437823	\$	378,273.25
149437821	\$	99,133.40
149437814	\$	94,690.40
186391629	\$	1,029,955.59
186391632	\$	67,028.10
186391630	\$	25,092.00
186391631	\$	22,829.44
186391628	\$	17,813.58
149437789	\$	132,988.50
149437783	\$	68,731.10
149437779	\$	294,079.95
149437772	\$	165,210.75
149437766	\$	533,137.50
149437763	\$	136,114.85
149078787	\$	82,542.72
149437758	\$	3,419,289.81
149437757	\$	974,466.56
149437756	\$	27,576,070.40



149437752	\$	6,120,467.34
149437751	\$	56,120.45
149437750	\$	1,291,493.75
149437748	\$	984,411.85
149437747	\$	106,494.24
149437732	\$	637,752.80
149437719	\$	91,034.42
149437718	\$	782,222.84
149078784	\$	39,695.30
149437705	\$	67,200.90
149437703	\$	2,183,848.99
149437702	\$	493,286.50
149437701	\$	526,338.79
149437694	\$	143,221.91
149437692	\$	230,432.54
149437691	\$	356,208.81
149437690	\$	962,056.06
149437683	\$	2,878,687.56
149437682	\$	148,902.00
149437681	\$	53,161.10
149437680	\$	2,061,139.39
149437679	\$	7,794.90
149437678	\$	81,339.00
149437665	\$	50,352.30
149437662	\$	1,119,618.00
149437636	\$	116,862.75
149437635	\$	495.60
149437621	\$	949,261.13
149437619	\$	9,407,159.38
149437611	\$	875,720.73
149437610	\$	139,726.16
149078780	\$	35,849.78
149437590	\$	39,795.75
149437580	\$	406,194.45
149437574	\$	157,459.48
149437566	\$	134,073.77
149437554	\$	18,589.75
149437551	\$	2,080,280.10
149437550	\$	29,785.43
149437530	\$	128,136.13
149437508	\$	91,490.85
149437473	\$	1,605,540.55
149437441	\$	76,459.20
149437396	\$	383.40
149437395	\$	23,313.50
149437394	\$	70,756.00
149437372	\$	157,515.60

149437323	\$	4,500.00
149437238	\$	43,160.55
149437237	\$	32,132.24
149078758	\$	72,342.02

# EXHIBIT F

**Exhibit Summary: Total Claims: 4 Claims; Total Qualifying Claims: \$1,169,666.34**

Claim Number	Authorized Claim
149438304 \$	3,118.04
149438299 \$	1,118,729.01
149438247 \$	28.29
149438238 \$	47,791.00

# EXHIBIT G

**Exhibit Summary: Total Claims: 1225**

ClaimNumber	Reason
149078756	Insufficient Response to Audit
149078757	Insufficient Response to Audit
149078759	Consumer Claim
149078760	No Purchase
149078761	Consumer Claim
149078762	Insufficient Response to Audit
149078763	Insufficient Response to Audit
149078764	Insufficient Response to Audit
149078765	Consumer Claim
149078766	Consumer Claim
149078767	Consumer Claim
149078768	Consumer Claim
149078769	Duplicate Claim
149078770	Consumer Claim
149078771	Duplicate Claim
149078772	Consumer Claim
149078773	Insufficient Response to Audit
149078774	Consumer Claim
149078775	Insufficient Response to Audit
149078776	Insufficient Response to Audit
149078777	Consumer Claim
149078778	Insufficient Response to Audit
149078779	Insufficient Response to Audit
149078781	Consumer Claim
149078782	Consumer Claim
149078783	Consumer Claim
149078785	Insufficient Response to Audit
149078786	Duplicate Claim
149078788	Duplicate Claim
149078789	Consumer Claim
149078790	Insufficient Response to Audit
149078791	Insufficient Response to Audit
149078792	Consumer Claim
149078793	Duplicate Claim
149078794	Consumer Claim
149078795	Consumer Claim
149078796	Consumer Claim
149078797	Consumer Claim
149078798	Consumer Claim
149078803	Insufficient Response to Audit
149078804	Insufficient Response to Audit
149078805	Consumer Claim
149078806	Consumer Claim
149436996	Insufficient Response to Audit
149436997	Consumer Claim
149436998	Consumer Claim
149436999	Consumer Claim
149437000	Consumer Claim
149437001	Consumer Claim
149437002	Insufficient Response to Audit

ClaimNumber	Reason
149437003	Consumer Claim
149437004	Consumer Claim
149437005	Consumer Claim
149437006	Consumer Claim
149437007	Consumer Claim
149437008	Consumer Claim
149437009	Consumer Claim
149437010	Insufficient Response to Audit
149437011	Consumer Claim
149437012	Consumer Claim
149437013	Consumer Claim
149437014	Consumer Claim
149437015	Consumer Claim
149437016	Duplicate Claim
149437017	Insufficient Response to Audit
149437018	Insufficient Response to Audit
149437019	Consumer Claim
149437020	Consumer Claim
149437021	Consumer Claim
149437022	Consumer Claim
149437023	Consumer Claim
149437024	Consumer Claim
149437025	Consumer Claim
149437026	Consumer Claim
149437027	Consumer Claim
149437028	Consumer Claim
149437029	Consumer Claim
149437030	Consumer Claim
149437031	Consumer Claim
149437032	Consumer Claim
149437033	Consumer Claim
149437034	Consumer Claim
149437035	Consumer Claim
149437036	Consumer Claim
149437037	Consumer Claim
149437038	Insufficient Response to Audit
149437039	Consumer Claim
149437040	Consumer Claim
149437041	Consumer Claim
149437042	Consumer Claim
149437043	Consumer Claim
149437044	Consumer Claim
149437045	Consumer Claim
149437046	Insufficient Response to Audit
149437047	Insufficient Response to Audit
149437048	Consumer Claim
149437049	Insufficient Response to Audit
149437050	Consumer Claim
149437051	Consumer Claim
149437052	Consumer Claim
149437053	Consumer Claim
149437054	Consumer Claim

ClaimNumber	Reason
149437055	Consumer Claim
149437056	Consumer Claim
149437057	Consumer Claim
149437058	Duplicate Claim
149437059	Consumer Claim
149437060	Consumer Claim
149437061	Consumer Claim
149437062	Consumer Claim
149437063	Consumer Claim
149437064	Consumer Claim
149437065	Duplicate Claim
149437066	Consumer Claim
149437067	Duplicate Claim
149437068	Consumer Claim
149437069	Consumer Claim
149437070	Consumer Claim
149437071	Consumer Claim
149437072	Duplicate Claim
149437073	Consumer Claim
149437074	Consumer Claim
149437075	Consumer Claim
149437076	Consumer Claim
149437077	Consumer Claim
149437078	Consumer Claim
149437079	Insufficient Response to Audit
149437080	Insufficient Response to Audit
149437081	Consumer Claim
149437082	Insufficient Response to Audit
149437083	Insufficient Response to Audit
149437084	Consumer Claim
149437085	Consumer Claim
149437086	Consumer Claim
149437087	Insufficient Response to Audit
149437088	Duplicate Claim
149437089	Insufficient Response to Audit
149437090	Insufficient Response to Audit
149437091	Insufficient Response to Audit
149437092	Insufficient Response to Audit
149437093	Insufficient Response to Audit
149437094	Duplicate Claim
149437095	Duplicate Claim
149437096	Duplicate Claim
149437097	Consumer Claim
149437098	Insufficient Response to Audit
149437099	Consumer Claim
149437100	Consumer Claim
149437101	Consumer Claim
149437102	Insufficient Response to Audit
149437103	Insufficient Response to Audit
149437104	Insufficient Response to Audit
149437105	Consumer Claim
149437106	Consumer Claim



ClaimNumber	Reason
149437107	Consumer Claim
149437108	Consumer Claim
149437109	Insufficient Response to Audit
149437110	Insufficient Response to Audit
149437111	Insufficient Response to Audit
149437112	Insufficient Response to Audit
149437113	Insufficient Response to Audit
149437114	Consumer Claim
149437115	Consumer Claim
149437116	Consumer Claim
149437117	Consumer Claim
149437118	Consumer Claim
149437119	Consumer Claim
149437120	Consumer Claim
149437121	Insufficient Response to Audit
149437122	Consumer Claim
149437123	Consumer Claim
149437124	Insufficient Response to Audit
149437125	Consumer Claim
149437126	Consumer Claim
149437127	Consumer Claim
149437128	Consumer Claim
149437129	Insufficient Response to Audit
149437130	Consumer Claim
149437131	Consumer Claim
149437132	Consumer Claim
149437133	Consumer Claim
149437134	Insufficient Response to Audit
149437135	Insufficient Response to Audit
149437136	Insufficient Response to Audit
149437137	Consumer Claim
149437138	Consumer Claim
149437139	Consumer Claim
149437140	Insufficient Response to Audit
149437141	Consumer Claim
149437142	Consumer Claim
149437143	Consumer Claim
149437144	Consumer Claim
149437145	Insufficient Response to Audit
149437146	Consumer Claim
149437147	Insufficient Response to Audit
149437148	Consumer Claim
149437149	Consumer Claim
149437150	Consumer Claim
149437151	Duplicate Claim
149437152	Consumer Claim
149437153	Consumer Claim
149437154	Consumer Claim
149437155	Consumer Claim
149437156	Consumer Claim
149437157	Duplicate Claim
149437158	Insufficient Response to Audit

ClaimNumber	Reason
149437159	Consumer Claim
149437160	Insufficient Response to Audit
149437161	Consumer Claim
149437162	Consumer Claim
149437163	Consumer Claim
149437164	Consumer Claim
149437165	Consumer Claim
149437166	Consumer Claim
149437167	Consumer Claim
149437168	Consumer Claim
149437169	Consumer Claim
149437170	Consumer Claim
149437171	Consumer Claim
149437172	Consumer Claim
149437173	Consumer Claim
149437174	Consumer Claim
149437175	Insufficient Response to Audit
149437176	Consumer Claim
149437177	Consumer Claim
149437178	Insufficient Response to Audit
149437179	Insufficient Response to Audit
149437180	Consumer Claim
149437181	Consumer Claim
149437182	Consumer Claim
149437183	Consumer Claim
149437184	Consumer Claim
149437185	Consumer Claim
149437186	Consumer Claim
149437187	Consumer Claim
149437188	Consumer Claim
149437189	Consumer Claim
149437190	Insufficient Response to Audit
149437191	Consumer Claim
149437192	Consumer Claim
149437193	Consumer Claim
149437194	Consumer Claim
149437195	Consumer Claim
149437196	Consumer Claim
149437197	Consumer Claim
149437198	Consumer Claim
149437199	Consumer Claim
149437200	Consumer Claim
149437201	Consumer Claim
149437202	Consumer Claim
149437203	Consumer Claim
149437204	Consumer Claim
149437205	Consumer Claim
149437206	Consumer Claim
149437207	Consumer Claim
149437208	Consumer Claim
149437209	Consumer Claim
149437210	Consumer Claim

ClaimNumber	Reason
149437211	Insufficient Response to Audit
149437212	Consumer Claim
149437213	Insufficient Response to Audit
149437214	Consumer Claim
149437215	Insufficient Response to Audit
149437216	Insufficient Response to Audit
149437217	Consumer Claim
149437218	Consumer Claim
149437219	Consumer Claim
149437220	Consumer Claim
149437221	Consumer Claim
149437222	Insufficient Response to Audit
149437223	Insufficient Response to Audit
149437224	Consumer Claim
149437225	Duplicate Claim
149437226	Consumer Claim
149437227	Consumer Claim
149437228	Consumer Claim
149437229	Consumer Claim
149437230	Insufficient Response to Audit
149437231	Consumer Claim
149437232	Insufficient Response to Audit
149437233	Consumer Claim
149437234	Consumer Claim
149437235	Consumer Claim
149437236	Consumer Claim
149437239	Consumer Claim
149437240	Consumer Claim
149437241	Consumer Claim
149437242	Consumer Claim
149437243	Consumer Claim
149437244	Consumer Claim
149437245	Insufficient Response to Audit
149437246	Consumer Claim
149437247	Consumer Claim
149437248	Consumer Claim
149437249	Consumer Claim
149437250	Consumer Claim
149437251	Duplicate Claim
149437252	Insufficient Response to Audit
149437253	Consumer Claim
149437254	Consumer Claim
149437255	Consumer Claim
149437256	Consumer Claim
149437257	Consumer Claim
149437258	Consumer Claim
149437259	Consumer Claim
149437260	Consumer Claim
149437261	Consumer Claim
149437262	Insufficient Response to Audit
149437263	Insufficient Response to Audit
149437264	Consumer Claim

ClaimNumber	Reason
149437265	Consumer Claim
149437266	Consumer Claim
149437267	Consumer Claim
149437268	Consumer Claim
149437269	Consumer Claim
149437270	Consumer Claim
149437271	Consumer Claim
149437272	Consumer Claim
149437273	Consumer Claim
149437274	Consumer Claim
149437275	Consumer Claim
149437276	Consumer Claim
149437277	Consumer Claim
149437278	Consumer Claim
149437279	Insufficient Response to Audit
149437280	Insufficient Response to Audit
149437281	Insufficient Response to Audit
149437282	Duplicate Claim
149437283	Consumer Claim
149437284	Consumer Claim
149437285	Consumer Claim
149437286	Insufficient Response to Audit
149437287	Consumer Claim
149437288	Insufficient Response to Audit
149437289	Consumer Claim
149437290	Consumer Claim
149437291	Consumer Claim
149437292	Consumer Claim
149437293	Insufficient Response to Audit
149437294	Insufficient Response to Audit
149437295	Consumer Claim
149437296	Consumer Claim
149437297	No Purchase
149437298	Consumer Claim
149437299	No Purchase
149437300	Consumer Claim
149437301	Consumer Claim
149437302	Duplicate Claim
149437303	Consumer Claim
149437304	Consumer Claim
149437305	Consumer Claim
149437306	Consumer Claim
149437307	Consumer Claim
149437308	Consumer Claim
149437309	Consumer Claim
149437310	Consumer Claim
149437311	Consumer Claim
149437312	Consumer Claim
149437313	Consumer Claim
149437314	Consumer Claim
149437315	Consumer Claim
149437316	Consumer Claim

ClaimNumber	Reason
149437317	Consumer Claim
149437318	Consumer Claim
149437319	Consumer Claim
149437320	Consumer Claim
149437321	Consumer Claim
149437322	Consumer Claim
149437324	Consumer Claim
149437325	Consumer Claim
149437326	Insufficient Response to Audit
149437327	Consumer Claim
149437328	Consumer Claim
149437329	Insufficient Response to Audit
149437330	Consumer Claim
149437331	Consumer Claim
149437332	Consumer Claim
149437333	Insufficient Response to Audit
149437334	Consumer Claim
149437335	Consumer Claim
149437336	Consumer Claim
149437337	Consumer Claim
149437338	Consumer Claim
149437339	Consumer Claim
149437340	Consumer Claim
149437341	Consumer Claim
149437342	Consumer Claim
149437343	Consumer Claim
149437344	Consumer Claim
149437345	Consumer Claim
149437346	Insufficient Response to Audit
149437347	Consumer Claim
149437348	Consumer Claim
149437349	Insufficient Response to Audit
149437350	Insufficient Response to Audit
149437351	Insufficient Response to Audit
149437352	Insufficient Response to Audit
149437353	Consumer Claim
149437354	Consumer Claim
149437355	Insufficient Response to Audit
149437356	Consumer Claim
149437357	Consumer Claim
149437358	Consumer Claim
149437359	Consumer Claim
149437360	Consumer Claim
149437361	Insufficient Response to Audit
149437362	Consumer Claim
149437363	Consumer Claim
149437364	Consumer Claim
149437365	Consumer Claim
149437366	Consumer Claim
149437367	Consumer Claim
149437368	Consumer Claim
149437369	Consumer Claim

ClaimNumber	Reason
149437370	Consumer Claim
149437371	Consumer Claim
149437373	Insufficient Response to Audit
149437374	Consumer Claim
149437375	Consumer Claim
149437376	Consumer Claim
149437377	Consumer Claim
149437378	Consumer Claim
149437379	Consumer Claim
149437380	Insufficient Response to Audit
149437381	Consumer Claim
149437382	Consumer Claim
149437383	Consumer Claim
149437384	Consumer Claim
149437385	Consumer Claim
149437386	Consumer Claim
149437387	Consumer Claim
149437388	Consumer Claim
149437389	Consumer Claim
149437390	Consumer Claim
149437391	Consumer Claim
149437392	Consumer Claim
149437393	Duplicate Claim
149437397	Insufficient Response to Audit
149437398	Duplicate Claim
149437399	Duplicate Claim
149437400	Consumer Claim
149437401	Insufficient Response to Audit
149437402	Consumer Claim
149437403	Consumer Claim
149437404	Duplicate Claim
149437405	Consumer Claim
149437406	Consumer Claim
149437407	Consumer Claim
149437408	Consumer Claim
149437409	Consumer Claim
149437410	Consumer Claim
149437411	Insufficient Response to Audit
149437412	Consumer Claim
149437413	Insufficient Response to Audit
149437414	Consumer Claim
149437415	Consumer Claim
149437416	Consumer Claim
149437417	Duplicate Claim
149437418	Consumer Claim
149437419	Consumer Claim
149437420	Consumer Claim
149437421	Consumer Claim
149437422	Insufficient Response to Audit
149437423	Consumer Claim
149437424	Consumer Claim
149437425	Duplicate Claim

ClaimNumber	Reason
149437426	Consumer Claim
149437427	Consumer Claim
149437428	Consumer Claim
149437429	Insufficient Response to Audit
149437430	Consumer Claim
149437431	Duplicate Claim
149437432	Consumer Claim
149437433	Insufficient Response to Audit
149437434	Insufficient Response to Audit
149437435	Consumer Claim
149437436	Consumer Claim
149437437	Consumer Claim
149437438	Consumer Claim
149437439	Consumer Claim
149437440	Consumer Claim
149437442	Consumer Claim
149437443	Consumer Claim
149437444	Insufficient Response to Audit
149437445	No Purchase
149437446	Consumer Claim
149437447	Consumer Claim
149437448	Consumer Claim
149437449	Consumer Claim
149437450	Insufficient Response to Audit
149437451	Consumer Claim
149437452	Consumer Claim
149437453	Consumer Claim
149437454	Consumer Claim
149437455	Consumer Claim
149437456	Consumer Claim
149437457	Consumer Claim
149437458	Consumer Claim
149437459	Consumer Claim
149437460	Consumer Claim
149437461	No Purchase
149437462	Consumer Claim
149437463	Consumer Claim
149437464	Consumer Claim
149437465	Consumer Claim
149437466	Consumer Claim
149437467	Consumer Claim
149437468	Consumer Claim
149437469	Insufficient Response to Audit
149437470	Consumer Claim
149437471	Consumer Claim
149437472	Insufficient Response to Audit
149437474	Consumer Claim
149437475	Consumer Claim
149437476	Consumer Claim
149437477	Consumer Claim
149437478	Consumer Claim
149437479	Consumer Claim

ClaimNumber	Reason
149437480	Consumer Claim
149437481	Consumer Claim
149437482	Consumer Claim
149437483	Consumer Claim
149437484	Consumer Claim
149437485	Consumer Claim
149437486	Insufficient Response to Audit
149437487	Consumer Claim
149437488	Consumer Claim
149437489	Consumer Claim
149437490	Consumer Claim
149437491	Duplicate Claim
149437492	Consumer Claim
149437493	Consumer Claim
149437494	Consumer Claim
149437495	Consumer Claim
149437496	Consumer Claim
149437497	Consumer Claim
149437498	Duplicate Claim
149437499	Duplicate Claim
149437500	Consumer Claim
149437501	Insufficient Response to Audit
149437502	Insufficient Response to Audit
149437503	Consumer Claim
149437504	Consumer Claim
149437505	Consumer Claim
149437506	Consumer Claim
149437507	Consumer Claim
149437509	Consumer Claim
149437510	Insufficient Response to Audit
149437511	Consumer Claim
149437512	Consumer Claim
149437513	Consumer Claim
149437514	Insufficient Response to Audit
149437515	Consumer Claim
149437516	Duplicate Claim
149437517	Consumer Claim
149437518	Consumer Claim
149437519	Consumer Claim
149437520	Consumer Claim
149437521	Consumer Claim
149437522	Duplicate Claim
149437523	Insufficient Response to Audit
149437524	Insufficient Response to Audit
149437525	Insufficient Response to Audit
149437526	Consumer Claim
149437527	Consumer Claim
149437528	Consumer Claim
149437529	Insufficient Response to Audit
149437531	Consumer Claim
149437532	Duplicate Claim
149437533	Consumer Claim



ClaimNumber	Reason
149437534	Consumer Claim
149437535	Consumer Claim
149437536	Insufficient Response to Audit
149437537	Consumer Claim
149437538	Consumer Claim
149437539	Insufficient Response to Audit
149437540	Consumer Claim
149437541	Consumer Claim
149437542	Consumer Claim
149437543	Consumer Claim
149437544	Consumer Claim
149437545	Consumer Claim
149437546	Consumer Claim
149437547	Consumer Claim
149437548	Consumer Claim
149437549	Insufficient Response to Audit
149437552	Consumer Claim
149437553	Consumer Claim
149437555	Consumer Claim
149437556	Consumer Claim
149437557	Insufficient Response to Audit
149437558	Consumer Claim
149437559	Duplicate Claim
149437560	Consumer Claim
149437561	Duplicate Claim
149437562	Consumer Claim
149437563	Consumer Claim
149437564	Consumer Claim
149437565	Insufficient Response to Audit
149437567	Insufficient Response to Audit
149437568	Insufficient Response to Audit
149437569	Consumer Claim
149437570	Insufficient Response to Audit
149437571	Consumer Claim
149437572	Insufficient Response to Audit
149437573	Consumer Claim
149437575	Insufficient Response to Audit
149437576	Consumer Claim
149437577	Consumer Claim
149437578	Insufficient Response to Audit
149437579	Consumer Claim
149437581	Insufficient Response to Audit
149437582	Insufficient Response to Audit
149437583	Consumer Claim
149437584	Consumer Claim
149437585	Consumer Claim
149437586	Consumer Claim
149437587	Insufficient Response to Audit
149437588	Insufficient Response to Audit
149437589	Duplicate Claim
149437591	Insufficient Response to Audit
149437592	Consumer Claim

ClaimNumber	Reason
149437593	Consumer Claim
149437594	Consumer Claim
149437595	Consumer Claim
149437596	Consumer Claim
149437597	Consumer Claim
149437598	Consumer Claim
149437599	Consumer Claim
149437600	Consumer Claim
149437601	Consumer Claim
149437602	Consumer Claim
149437603	Insufficient Response to Audit
149437604	Insufficient Response to Audit
149437605	Consumer Claim
149437606	Insufficient Response to Audit
149437607	Consumer Claim
149437608	Consumer Claim
149437609	Insufficient Response to Audit
149437612	Consumer Claim
149437613	Insufficient Response to Audit
149437614	Consumer Claim
149437615	Consumer Claim
149437616	Insufficient Response to Audit
149437617	Consumer Claim
149437618	Consumer Claim
149437620	Duplicate Claim
149437622	Insufficient Response to Audit
149437623	Insufficient Response to Audit
149437624	Consumer Claim
149437625	Insufficient Response to Audit
149437626	Duplicate Claim
149437627	Duplicate Claim
149437628	Insufficient Response to Audit
149437629	Insufficient Response to Audit
149437630	Consumer Claim
149437631	Duplicate Claim
149437632	Consumer Claim
149437633	Consumer Claim
149437634	Insufficient Response to Audit
149437637	Insufficient Response to Audit
149437638	Insufficient Response to Audit
149437639	Consumer Claim
149437640	Insufficient Response to Audit
149437641	Insufficient Response to Audit
149437642	Insufficient Response to Audit
149437643	Insufficient Response to Audit
149437644	Insufficient Response to Audit
149437645	Insufficient Response to Audit
149437646	Insufficient Response to Audit
149437647	Insufficient Response to Audit
149437648	Consumer Claim
149437649	Consumer Claim
149437650	Consumer Claim

ClaimNumber	Reason
149437651	Consumer Claim
149437652	Consumer Claim
149437653	Insufficient Response to Audit
149437654	Consumer Claim
149437655	Consumer Claim
149437656	Consumer Claim
149437657	Consumer Claim
149437658	Consumer Claim
149437659	Consumer Claim
149437660	Consumer Claim
149437661	Consumer Claim
149437663	Insufficient Response to Audit
149437664	Consumer Claim
149437666	Consumer Claim
149437667	Consumer Claim
149437668	Consumer Claim
149437669	Consumer Claim
149437670	Consumer Claim
149437671	Consumer Claim
149437672	Consumer Claim
149437673	Consumer Claim
149437674	Duplicate Claim
149437675	Consumer Claim
149437676	Insufficient Response to Audit
149437677	Consumer Claim
149437684	Consumer Claim
149437685	Consumer Claim
149437686	Consumer Claim
149437687	Consumer Claim
149437688	Consumer Claim
149437689	Consumer Claim
149437693	Consumer Claim
149437695	Insufficient Response to Audit
149437696	Consumer Claim
149437697	Insufficient Response to Audit
149437698	Insufficient Response to Audit
149437699	Insufficient Response to Audit
149437700	Duplicate Claim
149437704	Consumer Claim
149437706	Consumer Claim
149437707	Insufficient Response to Audit
149437708	Insufficient Response to Audit
149437709	Insufficient Response to Audit
149437710	Consumer Claim
149437711	Insufficient Response to Audit
149437712	Insufficient Response to Audit
149437713	Insufficient Response to Audit
149437714	Consumer Claim
149437715	Insufficient Response to Audit
149437716	Insufficient Response to Audit
149437717	Consumer Claim
149437720	Insufficient Response to Audit

ClaimNumber	Reason
149437721	Consumer Claim
149437722	Insufficient Response to Audit
149437723	Insufficient Response to Audit
149437724	Insufficient Response to Audit
149437725	Insufficient Response to Audit
149437726	Consumer Claim
149437727	Insufficient Response to Audit
149437728	Insufficient Response to Audit
149437729	Consumer Claim
149437730	Consumer Claim
149437731	Consumer Claim
149437733	Consumer Claim
149437734	Insufficient Response to Audit
149437735	Insufficient Response to Audit
149437736	Insufficient Response to Audit
149437737	Consumer Claim
149437738	Consumer Claim
149437739	Insufficient Response to Audit
149437740	Insufficient Response to Audit
149437741	Consumer Claim
149437742	Insufficient Response to Audit
149437743	Insufficient Response to Audit
149437744	Consumer Claim
149437745	Consumer Claim
149437746	Consumer Claim
149437749	Insufficient Response to Audit
149437753	Consumer Claim
149437754	Duplicate Claim
149437755	Duplicate Claim
149437759	Consumer Claim
149437760	Consumer Claim
149437761	Insufficient Response to Audit
149437762	Insufficient Response to Audit
149437764	Consumer Claim
149437765	Consumer Claim
149437767	Consumer Claim
149437768	Insufficient Response to Audit
149437769	Duplicate Claim
149437770	Insufficient Response to Audit
149437771	Duplicate Claim
149437773	Insufficient Response to Audit
149437774	Insufficient Response to Audit
149437775	Consumer Claim
149437776	Insufficient Response to Audit
149437777	Insufficient Response to Audit
149437778	Insufficient Response to Audit
149437780	Consumer Claim
149437781	No Purchase
149437782	No Purchase
149437784	Consumer Claim
149437785	Consumer Claim
149437786	Consumer Claim

ClaimNumber	Reason
149437787	Consumer Claim
149437788	Insufficient Response to Audit
149437790	Consumer Claim
149437791	Insufficient Response to Audit
149437792	Consumer Claim
149437793	Insufficient Response to Audit
149437794	Consumer Claim
149437795	Insufficient Response to Audit
149437796	Consumer Claim
149437797	Insufficient Response to Audit
149437798	Insufficient Response to Audit
149437799	Consumer Claim
149437800	Consumer Claim
149437801	Insufficient Response to Audit
149437802	No Purchase
149437803	No Purchase
149437804	No Purchase
149437805	No Purchase
149437806	No Purchase
149437807	No Purchase
149437808	No Purchase
149437809	No Purchase
149437810	No Purchase
149437811	No Purchase
149437812	No Purchase
149437813	No Purchase
149437815	No Purchase
149437816	No Purchase
149437817	No Purchase
149437818	Insufficient Response to Audit
149437819	Consumer Claim
149437820	Consumer Claim
149437822	Consumer Claim
149437824	Consumer Claim
149437825	Consumer Claim
149437826	Insufficient Response to Audit
149437827	Duplicate Claim
149437828	Consumer Claim
149437829	Insufficient Response to Audit
149437830	Consumer Claim
149437831	Insufficient Response to Audit
149437832	Insufficient Response to Audit
149437833	Insufficient Response to Audit
149437834	Consumer Claim
149437835	Consumer Claim
149437836	Consumer Claim
149437838	Consumer Claim
149437840	Duplicate Claim
149437843	Consumer Claim
149437845	Insufficient Response to Audit
149437846	Insufficient Response to Audit
149437847	Insufficient Response to Audit

ClaimNumber	Reason
149437848	Consumer Claim
149437851	Consumer Claim
149437852	Insufficient Response to Audit
149437853	Consumer Claim
149437854	Consumer Claim
149437856	Claim Withdrawn
149437857	Consumer Claim
149437858	Consumer Claim
149437859	Consumer Claim
149437860	Insufficient Response to Audit
149437861	Insufficient Response to Audit
149437862	Consumer Claim
149437863	Insufficient Response to Audit
149437864	Consumer Claim
149437865	Duplicate Claim
149437866	Consumer Claim
149437867	Insufficient Response to Audit
149437868	Insufficient Response to Audit
149437869	Insufficient Response to Audit
149437870	Insufficient Response to Audit
149437871	Consumer Claim
149437872	Duplicate Claim
149437873	Consumer Claim
149437874	Insufficient Response to Audit
149437875	Insufficient Response to Audit
149437876	Insufficient Response to Audit
149437877	Insufficient Response to Audit
149437878	Insufficient Response to Audit
149437879	Duplicate Claim
149437881	Insufficient Response to Audit
149437882	Insufficient Response to Audit
149437884	Claim Withdrawn
149437885	Claim Withdrawn
149437886	Insufficient Response to Audit
149437887	Insufficient Response to Audit
149437888	Insufficient Response to Audit
149437889	Insufficient Response to Audit
149437890	Consumer Claim
149437891	Consumer Claim
149437892	Consumer Claim
149437893	Consumer Claim
149437894	Claim Withdrawn
149437895	Insufficient Response to Audit
149437896	Insufficient Response to Audit
149437897	Insufficient Response to Audit
149437898	Insufficient Response to Audit
149437899	Insufficient Response to Audit
149437900	Insufficient Response to Audit
149437901	Consumer Claim
149437902	Consumer Claim
149437903	Insufficient Response to Audit
149437904	Consumer Claim

ClaimNumber	Reason
149437905	Insufficient Response to Audit
149437906	Duplicate Claim
149437907	Consumer Claim
149437908	Insufficient Response to Audit
149437910	Insufficient Response to Audit
149437911	Insufficient Response to Audit
149437913	Insufficient Response to Audit
149437914	Insufficient Response to Audit
149437915	Insufficient Response to Audit
149437917	Consumer Claim
149437918	Consumer Claim
149437919	Insufficient Response to Audit
149437920	Insufficient Response to Audit
149437921	Insufficient Response to Audit
149437922	Insufficient Response to Audit
149437923	Insufficient Response to Audit
149437924	Insufficient Response to Audit
149437925	Insufficient Response to Audit
149437926	Insufficient Response to Audit
149437927	Insufficient Response to Audit
149437928	Duplicate Claim
149437929	Insufficient Response to Audit
149437930	Consumer Claim
149437932	Insufficient Response to Audit
149437934	Insufficient Response to Audit
149437935	Insufficient Response to Audit
149437939	Insufficient Response to Audit
149437941	Consumer Claim
149437942	Consumer Claim
149437943	Consumer Claim
149437944	Duplicate Claim
149437945	Insufficient Response to Audit
149437946	Insufficient Response to Audit
149437947	Insufficient Response to Audit
149437948	Duplicate Claim
149437950	Insufficient Response to Audit
149437952	Insufficient Response to Audit
149437953	Consumer Claim
149437954	Insufficient Response to Audit
149437955	Consumer Claim
149437956	Claim Withdrawn
149437957	Insufficient Response to Audit
149437958	Claim Withdrawn
149437959	Claim Withdrawn
149437960	No Purchase
149437961	Claim Withdrawn
149437962	Insufficient Response to Audit
149437965	Insufficient Response to Audit
149437966	Duplicate Claim
149437969	Consumer Claim
149437970	Consumer Claim
149437971	Consumer Claim

ClaimNumber	Reason
149437972	Consumer Claim
149437973	Consumer Claim
149437974	Consumer Claim
149437975	Insufficient Response to Audit
149437976	Insufficient Response to Audit
149437977	Consumer Claim
149437978	Consumer Claim
149437979	Consumer Claim
149437980	Insufficient Response to Audit
149437984	No Purchase
149437985	Consumer Claim
149437988	Insufficient Response to Audit
149437990	Insufficient Response to Audit
149437991	Insufficient Response to Audit
149437992	Claim Withdrawn
149437994	Insufficient Response to Audit
149437996	Claim Withdrawn
149437997	Claim Withdrawn
149437998	Claim Withdrawn
149437999	Insufficient Response to Audit
149438000	Insufficient Response to Audit
149438001	Consumer Claim
149438002	Insufficient Response to Audit
149438003	Consumer Claim
149438004	Consumer Claim
149438005	Insufficient Response to Audit
149438006	Insufficient Response to Audit
149438007	Insufficient Response to Audit
149438008	Insufficient Response to Audit
149438009	Insufficient Response to Audit
149438010	Duplicate Claim
149438011	Insufficient Response to Audit
149438012	Insufficient Response to Audit
149438013	Insufficient Response to Audit
149438014	Consumer Claim
149438015	Insufficient Response to Audit
149438016	Consumer Claim
149438017	Insufficient Response to Audit
149438018	Consumer Claim
149438019	Insufficient Response to Audit
149438020	Consumer Claim
149438021	Insufficient Response to Audit
149438022	Consumer Claim
149438023	Consumer Claim
149438024	Insufficient Response to Audit
149438025	Insufficient Response to Audit
149438026	Duplicate Claim
149438027	Consumer Claim
149438028	Consumer Claim
149438029	Consumer Claim
149438030	Consumer Claim
149438031	Consumer Claim



ClaimNumber	Reason
149438032	Consumer Claim
149438033	Consumer Claim
149438034	Consumer Claim
149438035	Insufficient Response to Audit
149438036	Consumer Claim
149438037	Consumer Claim
149438038	Consumer Claim
149438039	Insufficient Response to Audit
149438040	Consumer Claim
149438042	Insufficient Response to Audit
149438043	Insufficient Response to Audit
149438044	Insufficient Response to Audit
149438045	Insufficient Response to Audit
149438046	No Purchase
149438047	Insufficient Response to Audit
149438048	Insufficient Response to Audit
149438049	Insufficient Response to Audit
149438050	Insufficient Response to Audit
149438051	Consumer Claim
149438052	Consumer Claim
149438053	Consumer Claim
149438054	Consumer Claim
149438055	Consumer Claim
149438056	Insufficient Response to Audit
149438057	Consumer Claim
149438058	Consumer Claim
149438059	Consumer Claim
149438060	Insufficient Response to Audit
149438061	Insufficient Response to Audit
149438062	Insufficient Response to Audit
149438063	Insufficient Response to Audit
149438064	Insufficient Response to Audit
149438065	Consumer Claim
149438066	Consumer Claim
149438067	No Purchase
149438068	Consumer Claim
149438071	Consumer Claim
149438072	Insufficient Response to Audit
149438073	Claim Withdrawn
149438074	Insufficient Response to Audit
149438075	Consumer Claim
149438076	Claim Withdrawn
149438077	Insufficient Response to Audit
149438078	Claim Withdrawn
149438079	Claim Withdrawn
149438080	Consumer Claim
149438081	Consumer Claim
149438082	Claim Withdrawn
149438083	Claim Withdrawn
149438088	Claim Withdrawn
149438089	Consumer Claim
149438090	Insufficient Response to Audit

ClaimNumber	Reason
149438091	Claim Withdrawn
149438092	Consumer Claim
149438093	Insufficient Response to Audit
149438094	Insufficient Response to Audit
149438095	Insufficient Response to Audit
149438096	Consumer Claim
149438097	Insufficient Response to Audit
149438098	Insufficient Response to Audit
149438099	Insufficient Response to Audit
149438101	Consumer Claim
149438103	Duplicate Claim
149438104	Insufficient Response to Audit
149438105	Consumer Claim
149438106	Insufficient Response to Audit
149438107	Insufficient Response to Audit
149438108	Insufficient Response to Audit
149438110	Consumer Claim
149438111	Insufficient Response to Audit
149438113	Consumer Claim
149438114	Insufficient Response to Audit
149438117	Claim Withdrawn
149438118	Insufficient Response to Audit
149438119	Consumer Claim
149438120	Insufficient Response to Audit
149438121	Insufficient Response to Audit
149438122	Insufficient Response to Audit
149438123	Consumer Claim
149438125	Insufficient Response to Audit
149438126	Consumer Claim
149438127	Insufficient Response to Audit
149438128	Consumer Claim
149438129	Consumer Claim
149438130	Consumer Claim
149438131	Consumer Claim
149438132	Duplicate Claim
149438133	Insufficient Response to Audit
149438134	Insufficient Response to Audit
149438135	Consumer Claim
149438136	Insufficient Response to Audit
149438137	Duplicate Claim
149438138	Consumer Claim
149438139	Consumer Claim
149438140	No Purchase
149438141	Consumer Claim
149438142	Claim Withdrawn
149438143	Consumer Claim
149438144	Consumer Claim
149438145	Consumer Claim
149438146	Claim Withdrawn
149438147	Claim Withdrawn
149438148	Claim Withdrawn
149438149	Claim Withdrawn

ClaimNumber	Reason
149438150	Insufficient Response to Audit
149438152	Consumer Claim
149438153	Insufficient Response to Audit
149438154	Consumer Claim
149438155	Insufficient Response to Audit
149438162	Insufficient Response to Audit
149438163	Consumer Claim
149438167	Consumer Claim
149438170	Consumer Claim
149438171	Consumer Claim
149438172	Claim Withdrawn
149438176	Consumer Claim
149438177	Claim Withdrawn
149438178	Consumer Claim
149438179	Consumer Claim
149438181	Consumer Claim
149438182	Consumer Claim
149438183	Consumer Claim
149438186	Duplicate Claim
149438189	Insufficient Response to Audit
149438191	Consumer Claim
149438192	Consumer Claim
149438193	Consumer Claim
149438194	Consumer Claim
149438195	Duplicate Claim
149438196	Consumer Claim
149438197	Insufficient Response to Audit
149438198	Consumer Claim
149438199	Insufficient Response to Audit
149438200	Insufficient Response to Audit
149438201	Insufficient Response to Audit
149438202	Consumer Claim
149438203	Consumer Claim
149438204	Duplicate Claim
149438205	Consumer Claim
149438206	Claim Withdrawn
149438207	Consumer Claim
149438208	Consumer Claim
149438209	Consumer Claim
149438210	Insufficient Response to Audit
149438211	Consumer Claim
149438212	Consumer Claim
149438213	Consumer Claim
149438214	Consumer Claim
149438215	Consumer Claim
149438216	Consumer Claim
149438217	Consumer Claim
149438218	Consumer Claim
149438219	Duplicate Claim
149438220	Insufficient Response to Audit
149438221	Consumer Claim
149438222	Consumer Claim

ClaimNumber	Reason
149438223	Consumer Claim
149438224	Consumer Claim
149438225	Consumer Claim
149438226	Consumer Claim
149438227	Consumer Claim
149438228	Consumer Claim
149438229	Insufficient Response to Audit
149438230	Consumer Claim
149438231	Consumer Claim
149438232	Consumer Claim
149438233	Consumer Claim
149438234	Consumer Claim
149438235	Consumer Claim
149438236	Consumer Claim
149438237	Consumer Claim
149438239	Consumer Claim
149438240	Consumer Claim
149438241	Insufficient Response to Audit
149438242	Duplicate Claim
149438243	Consumer Claim
149438244	Insufficient Response to Audit
149438245	Consumer Claim
149438246	Consumer Claim
149438248	Consumer Claim
149438249	Consumer Claim
149438250	Duplicate Claim
149438251	Consumer Claim
149438252	Consumer Claim
149438253	Consumer Claim
149438254	Consumer Claim
149438255	Consumer Claim
149438256	Consumer Claim
149438257	Consumer Claim
149438258	Insufficient Response to Audit
149438259	Consumer Claim
149438260	Consumer Claim
149438261	Consumer Claim
149438262	Consumer Claim
149438263	Consumer Claim
149438264	Consumer Claim
149438265	Insufficient Response to Audit
149438266	Insufficient Response to Audit
149438267	Insufficient Response to Audit
149438268	Consumer Claim
149438269	Insufficient Response to Audit
149438270	Insufficient Response to Audit
149438271	Consumer Claim
149438272	Consumer Claim
149438273	Duplicate Claim
149438274	Duplicate Claim
149438275	Insufficient Response to Audit
149438276	Insufficient Response to Audit

ClaimNumber	Reason
149438277	Insufficient Response to Audit
149438278	Insufficient Response to Audit
149438279	Consumer Claim
149438280	Insufficient Response to Audit
149438281	Insufficient Response to Audit
149438282	Consumer Claim
149438283	Insufficient Response to Audit
149438284	Insufficient Response to Audit
149438285	Insufficient Response to Audit
149438286	Insufficient Response to Audit
149438287	Insufficient Response to Audit
149438288	Insufficient Response to Audit
149438289	Insufficient Response to Audit
149438290	Insufficient Response to Audit
149438291	Insufficient Response to Audit
149438292	No Purchase
149438293	Consumer Claim
149438294	Insufficient Response to Audit
149438295	Insufficient Response to Audit
149438296	Insufficient Response to Audit
149438297	Insufficient Response to Audit
149438298	Insufficient Response to Audit
149438300	Consumer Claim
149438301	Consumer Claim
149438302	Consumer Claim
149438303	Consumer Claim
149438305	Consumer Claim
186391626	Consumer Claim
186391627	Claim Withdrawn
186391633	No Purchase
188592257	Consumer Claim

# EXHIBIT H



A.B. Data, Ltd.  
Class Action Administration Company  
600 A.B. Data Drive  
Milwaukee, WI 53217

Date: August 14, 2024  
Case Name: Daraprim TPP

<b>Distribution Estimate</b>			
Professional Fees			6,406.25
Printing and Mailing			1,862.50
Website & Telephone Charges			1,700.00
Tax Reporting and Miscellaneous Out-of-Pocket Expenses			6,070.00
<b>Total Estimated Project Cost</b>			<b>\$ 16,038.75</b>

**IN THE UNITED STATES DISTRICT COURT FOR  
THE SOUTHERN DISTRICT OF NEW YORK**

BCBSM, INC., d/b/a BLUE CROSS and  
BLUE SHIELD OF MINNESOTA, on  
behalf of itself and those similarly situated,

Plaintiff,

v.

VYERA PHARMACEUTICALS, LLC,  
PHOENIXUS AG, MARTIN SHKRELI, and  
KEVIN MULLEADY,

Defendants.

Case No. 1:21-cv-1884-DLC

**DECLARATION OF WILLIAM V. REISS IN SUPPORT OF SETTLEMENT CLASS  
COUNSEL’S MOTION FOR AN ORDER AUTHORIZING DISTRIBUTION OF THE  
NET SETTLEMENT FUND**

I, William V. Reiss, declare as follows:

1. I am a partner at Robins Kaplan LLP (“Robins Kaplan”). I make this declaration in support of Settlement Class Counsel’s Motion for an Order Authorizing Distribution of the Net Settlement Fund. I have personal knowledge of the facts stated herein based on my review of the pertinent filings and documents, and my discussions with former Robins Kaplan partner and Settlement Class Counsel, Benjamin Steinberg. If called upon to do so, I could and would testify competently thereto.

2. In connection with their role as Settlement Class Counsel, Robins Kaplan’s attorneys selected Huntington National Bank as escrow agent for the Class Settlement Fund and have worked with Huntington National Bank to create the Class Settlement Fund and maintain its assets. I have reviewed the Class Settlement Fund Ledger created by Huntington National Bank and am familiar with the deposits that were made into the account and the withdrawals that were made from the account.



3. On February 22, 2022, Defendants<sup>1</sup> paid \$7 million into the Class Settlement Fund.

4. Between May 9, 2022, and October 27, 2023, Defendants have made five contingent payments into the Class Settlement Fund, which total \$1,786,436.08. On May 9, 2022, Defendants transferred \$560,000.00. On August 30, 2022, Defendants transferred \$859,119.96. On February 9, 2023, Defendants transferred \$167,244.00. On April 12, 2023, Defendants transferred \$140,000.00. On October 27, 2023, Defendants transferred \$60,072.12.

5. I do not anticipate that Defendants will make additional contingent payments in the near term.

6. As of October 3, 2024 the current balance of the Class Settlement Fund was \$7,137,410.39, which accounts for both interest earned on the settlement payments and withdrawals for settlement-administration expenses, taxes, and Court-authorized attorney's fees and expenses.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed this 6th day of November, 2024, at New York, New York.

By: /s/ William V. Reiss  
William V. Reiss

---

<sup>1</sup> Where otherwise not defined, the capitalized terms used herein mirror the defined terms in the January 28, 2022 Settlement Agreement, Dkt.138-1, and the Final Judgment and Order of Dismissal. Dkt. 160.

**IN THE UNITED STATES DISTRICT COURT FOR  
THE SOUTHERN DISTRICT OF NEW YORK**

BCBSM, INC., d/b/a BLUE CROSS and  
BLUE SHIELD OF MINNESOTA, on  
behalf of itself and those similarly situated,

Plaintiff,

v.

VYERA PHARMACEUTICALS, LLC,  
PHOENIXUS AG, MARTIN SHKRELI, and  
KEVIN MULLEADY,

Defendants.

Case No. 1:21-cv-1884-DLC

**[PROPOSED] ORDER**  
**AUTHORIZING DISTRIBUTION OF THE NET SETTLEMENT FUND**

On June 17, 2022, this Court entered a Final Judgment and Order of Dismissal certifying the Settlement Class and granting final approval of the class Settlement between Plaintiff BCBSM, Inc. (“Plaintiff”) and Defendants Vyera Pharmaceuticals, LLC, Phoenixus AG, Martin Shkreli, and Kevin Mulleady (collectively, “Defendants”). Dkt. 160. The Court previously approved a Notice Plan and Plan of Allocation for the Settlement and appointed A.B. Data as Notice Provider and Claims Administrator. Dkt.141 at 5–7.

Under the Plan of Allocation, Dkt. 140-2 at 9–10, the money paid into the Class Settlement Fund shall be allocated on a *pro rata* basis to eligible members of the Settlement Class who submit valid claims, less deductions made for taxes, settlement administration expenses, attorneys’ fees, litigation costs, incentive awards, and any other charges authorized by the Court (the “Net Settlement Fund”). To effectuate this distribution, Settlement Class Counsel have filed a Motion for an Order Authorizing Distribution of the Net Settlement Fund (the “Motion”).

In support, Settlement Class Counsel have submitted the Declaration of Eric J. Miller, Senior Vice President of A.B. Data, which details the steps taken to process claims along with the Declaration of William V. Reiss. Settlement Class Counsel have requested that late-filed claims submitted on or before October 17, 2022 that are otherwise valid be accepted, as the equities favor distribution to these claimants.

Accordingly, and the Court being otherwise sufficiently advised,

**IT IS HEREBY ORDERED** that Settlement Class Counsel's Motion is **GRANTED** as follows:

1. The Claims Administrator's administrative determinations concerning the submitted claims are approved.

2. The two late-filed claims reflected on Exhibit F to the Miller Declaration are approved as eligible for distribution.

3. The Claims Administrator shall distribute the Net Settlement Fund on a *pro rata* basis to approved claimants and may reserve up to: (1) 5% of the Net Settlement Fund to account for any adjustments in payments or to pay additional taxes, costs, and administration fees; and (2) \$159,384.17 to cover Settlement Class Counsel's request for supplemental attorneys' fees and litigation expenses.

IT IS SO ORDERED on this \_\_\_\_ day of \_\_\_\_\_, 2024.

---

Hon. Denise L. Cote  
United States District Judge